Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Countries and organisations

Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.

Free access · No subscription for research tools or data exports

Explore registry geography and organisations

Reset

308 trials match this view; 461 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 15,051 across 308 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

200411
200711
200811
200922
201222
201322
201433
201533
201611
201755
201844
201999
20201010
20212525
20222424
20234040
20244949
20255252
20266868
202755
202911

Current indexed registry status

Recruiting103103
Completed9797
Active, not recruiting3333
Not yet recruiting3333
Unknown status1616
Withdrawn1414
Terminated77
Enrolling by invitation33
Suspended22

Reported research conditions

PTSD1313

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Countries with reported trial locations

Canada4141

Sponsors recorded in this index

Matching trial records

308 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation

NCT07818564

Phase I
Brown University

PHASE1

Recruiting

Registry updated 2026-10-08

24

ESTIMATED

2026-11
2027-11
2027-11
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease

NCT07721467

Alzheimer's Disease
National Institute on Aging (NIA)

PHASE2

Recruiting

Registry updated 2026-10-08

200

ESTIMATED

2026-10-13
2030-12-31
2030-12-31
Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial

NCT06386003

Post Traumatic Stress Disorder · PTSD · Chronic PTSD
Unity Health Toronto

PHASE2

Active, not recruiting

Registry updated 2026-10-06

15

ESTIMATED

2026-06-01
2028-01
2028-06
A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

NCT07570654

PTSD - Post Traumatic Stress Disorder · PTSD · PTSD Symptoms · PTSD, Post Traumatic Stress Disorder
COMPASS Pathways

PHASE2, PHASE3

Recruiting

Registry updated 2026-10-06

300

ESTIMATED

2026-09
2028-11
2029-09
Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive Impairment

NCT06041152

Amnestic Mild Cognitive Impairment
Centre for Addiction and Mental Health

PHASE2

Completed

Registry updated 2026-10-05

10

ACTUAL

2023-11-27
2026-02-19
2026-02-19
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

NCT07227909

Psilocybin · Neuropathy
M.D. Anderson Cancer Center

PHASE2

Not yet recruiting

Registry updated 2026-10-05

83

ESTIMATED

2026-11-04
2029-01-31
2031-01-31
Open-label, Single-arm fMRI Study Evaluating the Effects of Psilocybin on Craving in Nicotine Dependence.

NCT07852832

Nicotine Dependence
University of British Columbia

PHASE2

Not yet recruiting

Registry updated 2026-10-01

3

ESTIMATED

2027-01
2027-12
2028-01
PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment

NCT07610135

Mood (Psychological Function) · Well Being · Mood · Healthy
Johns Hopkins University

PHASE1, PHASE2

Recruiting

Registry updated 2026-10-01

20

ESTIMATED

2026-10-30
2028-06
2028-12
The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD

NCT07332143

PTSD
Emory University

PHASE2

Recruiting

Registry updated 2026-10-01

150

ESTIMATED

2026-06-08
2027-03
2027-03
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

NCT07360301

Well-Being, Psychological · Psychedelic Experiences
University of Wisconsin, Madison

PHASE1

Not yet recruiting

Registry updated 2026-09-29

120

ESTIMATED

2026-10
2028-02
2028-02
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

NCT07610369

Depression · Parkinson's Disease (PD)
Yale University

PHASE2

Recruiting

Registry updated 2026-09-28

40

ESTIMATED

2026-07-10
2030-07
2030-07
Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study

NCT07449351

Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI
Yale University

EARLY_PHASE1

Not yet recruiting

Registry updated 2026-09-24

20

ESTIMATED

2026-10-01
2028-04-01
2028-04-01
Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial

NCT06299319

Obsessive-Compulsive Disorder
Centre for Addiction and Mental Health

PHASE1

Completed

Registry updated 2026-09-24

10

ACTUAL

2024-09-01
2026-09-04
2026-09-04
Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial

NCT07296094

Alcohol Use Disorder
Brigham and Women's Hospital

PHASE2

Not yet recruiting

Registry updated 2026-09-24

36

ESTIMATED

2026-11-15
2029-12-01
2030-02
Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study

NCT06988319

Chronic Pelvic Pain
Oregon Health and Science University

PHASE1

Recruiting

Registry updated 2026-09-23

15

ESTIMATED

2026-11-01
2027-12-31
2027-12-31
ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted Therapy

NCT07833761

Borderline Personality Disorder · Borderline Personality Pathology · Depressive Symptoms · Emotion Dysregulation · Suicidal Ideation
University of Minnesota

PHASE1

Not yet recruiting

Registry updated 2026-09-22

18

ESTIMATED

2026-12-01
2029-12-31
2030-12-31
Psilocybin in the Treatment of Methamphetamine Use Disorder

NCT07774702

Methamphetamine Use Disorder
Peter Hendricks

PHASE2

Not yet recruiting

Registry updated 2026-09-21

42

ESTIMATED

2027-02-01
2032-02-01
2032-02-01
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)

NCT07210112

Depression - Major Depressive Disorder · Treatment-resistant Depression (TRD)
Centre Hospitalier St Anne

PHASE2

Recruiting

Registry updated 2026-09-21

112

ESTIMATED

2026-06-30
2029-12-31
2030-06-30
A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

NCT07516405

Healthy Volunteer · Older Adults (65-85 Years)
University of Colorado, Denver

PHASE1

Recruiting

Registry updated 2026-09-16

40

ESTIMATED

2026-04-01
2028-03
2028-03
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial

NCT07820033

Advanced Cancer · Stage IV Solid Tumor Cancer · Stage IV Sarcoma of Bone · Stage IV Lymphoma · Stage IV Melanoma · Endocrine Cancer
University Health Network, Toronto

PHASE2

Not yet recruiting

Registry updated 2026-09-15

46

ESTIMATED

2026-09-14
2028-12-30
2029-07-30
PRoMiSS: Psilocybin and the Role of Music in Set and Setting

NCT07180108

Psilocybin · Music Intervention
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-09-15

100

ESTIMATED

2025-08-12
2028-06
2028-08
Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia

NCT07607938

Anhedonia · Emotional Blunting
NYU Langone Health

PHASE1

Recruiting

Registry updated 2026-09-15

90

ESTIMATED

2026-09
2030-08-01
2030-09-30
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial

NCT06943573

Bipolar II Depression
Lakshmi N Yatham

PHASE2

Recruiting

Registry updated 2026-09-15

90

ESTIMATED

2026-06-15
2028-12
2028-12
A Phase 1b Study to Evaluate the Safety and Tolerability of MLS101 Treatment for Premenstrual Dysphoric Disorder (PMDD)

NCT07818720

Premenstrual Dysphoric Disorder ( PMDD) · PMDD
MycoMedica Life Sciences PBC

PHASE1

Not yet recruiting

Registry updated 2026-09-14

32

ESTIMATED

2026-12
2027-09
2027-12
Psilocybin Administration With 5-HT1a Blockade

NCT07565493

Psychedelic Effects in Healthy Volunteers
Johns Hopkins University

EARLY_PHASE1

Recruiting

Registry updated 2026-09-14

18

ESTIMATED

2026-08-12
2028-06-15
2028-06-15
TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

NCT06200155

Depression, Anxiety · Psilocybin-Assisted Psychotherapy · Advanced Cancer
M.D. Anderson Cancer Center

PHASE2

Recruiting

Registry updated 2026-09-11

48

ESTIMATED

2024-04-16
2026-12-31
2026-12-31
A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial

NCT06615908

Persisting Symptoms After Concussion
University of Calgary

PHASE1

Recruiting

Registry updated 2026-09-09

40

ESTIMATED

2025-05-27
2027-06-30
2027-12-30
A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease

NCT07386730

Anhedonia in Healthy Volunteers · Older Adults (50-90 Years)
Jennifer Mitchell

PHASE1

Recruiting

Registry updated 2026-09-09

80

ESTIMATED

2026-06-01
2030-02
2030-02
Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence

NCT06885996

Post Traumatic Stress Disorder PTSD · Intimate Partner Violence (IPV)
University of Calgary

PHASE2

Not yet recruiting

Registry updated 2026-09-08

76

ESTIMATED

2026-10-01
2028-08-01
2029-08-01
Effects of Psilocybin in Obsessive Compulsive Disorder

NCT05546658

Obsessive-Compulsive Disorder
Johns Hopkins University

EARLY_PHASE1

Active, not recruiting

Registry updated 2026-09-04

35

ACTUAL

2022-11-28
2026-12-30
2027-09-12
Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive Symptoms · Depression · Alzheimer Disease · Mild Cognitive Impairment
Johns Hopkins University

EARLY_PHASE1

Recruiting

Registry updated 2026-09-04

20

ESTIMATED

2021-03-24
2027-06-30
2027-09-30
Psilocybin and Affective Function in Chronic Lower Back Pain Depression

NCT06355414

Chronic Low-back Pain · Depression
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-09-04

40

ESTIMATED

2024-04-22
2026-12-30
2026-12-30
Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)

NCT06989957

Posttraumatic Stress Disorder
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-09-04

40

ESTIMATED

2025-09-17
2028-08
2029-08
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission

NCT06430541

Breast Cancer · Ovarian Cancer
University of Colorado, Denver

PHASE1

Recruiting

Registry updated 2026-09-04

20

ESTIMATED

2024-11-21
2026-12
2028-12
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study

NCT04932434

Parkinson Disease · Depression · Anxiety
Joshua Woolley, MD, PhD

PHASE2

Completed

Registry updated 2026-09-03

12

ACTUAL

2021-08-15
2024-12-31
2024-12-31
High vs. Low-Dose Group-Based Psilocybin-Assisted Therapy (PAT) With or Without Mindfulness-Based (MB) Preparation and Integration for Demoralization in Adults With Advanced Cancer (PAT-MIND): A Pilot Feasibility 2x2 Factorial Multisite Trial

NCT07791901

Advanced Cancer · Demoralization · Existential Distress · Psychological Distress
University of Calgary

PHASE2

Not yet recruiting

Registry updated 2026-09-02

60

ESTIMATED

2026-10-30
2027-12-20
2027-12-31
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder

NCT06349083

Alcohol Use Disorder
NYU Langone Health

PHASE2

Recruiting

Registry updated 2026-09-02

200

ESTIMATED

2026-09-01
2030-05
2030-05
The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults

NCT06768944

Investigating the Importance of the Subjective Psychedelic Experience
University of Calgary

PHASE2

Recruiting

Registry updated 2026-09-02

128

ESTIMATED

2026-05-15
2027-12
2028-01
Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]

NCT06814522

Burnout · Burnout, Healthcare Workers
University of California, San Diego

PHASE1, PHASE2

Recruiting

Registry updated 2026-09-02

30

ESTIMATED

2025-01-13
2028-06
2028-08
An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study

NCT06225232

Cannabis Use Disorder, Moderate · Cannabis Use Disorder, Severe
McMaster University

PHASE2

Active, not recruiting

Registry updated 2026-08-31

16

ESTIMATED

2025-03-21
2026-12
2026-12
Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study

NCT07792538

Posttraumatic Stress Disorder (PTSD)
ARQ National Psychotrauma Centre

PHASE2

Not yet recruiting

Registry updated 2026-08-28

12

ESTIMATED

2026-12
2028-12
2028-12
A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study

NCT04959253

Treatment Resistant Depression
King's College London

PHASE2

Completed

Registry updated 2026-08-28

60

ACTUAL

2021-06-21
2024-12-18
2024-12-18
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial

NCT07211438

Treatment-Resistant Depression
Centre for Addiction and Mental Health

PHASE2

Recruiting

Registry updated 2026-08-21

40

ESTIMATED

2026-07-03
2028-07
2029-01
Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes

NCT07306364

Chronic Low Back Pain (CLBP) · Physical Therapy · Psilocybin
Yale University

PHASE2

Not yet recruiting

Registry updated 2026-08-19

45

ESTIMATED

2026-10
2029-06
2029-06
An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal Cancers

NCT05220046

Pancreas Cancer · Biliary Tract Cancer · Psychological Distress · Gastrointestinal Cancer
University of Nebraska

PHASE1

Completed

Registry updated 2026-08-19

18

ACTUAL

2023-04-10
2025-11-17
2025-11-17
An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life

NCT07719088

Aging · Longevity · Biomarkers of Aging
Charles Raison

PHASE1

Not yet recruiting

Registry updated 2026-08-17

50

ESTIMATED

2026-12
2028-04
2028-12
The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults

NCT07169747

Anorexia Nervosa
Region Skane

PHASE2

Recruiting

Registry updated 2026-08-14

40

ESTIMATED

2026-07-20
2027-10-01
2027-10-01
Safety for Home Administration of Microdose Psilocybin Use

NCT06450210

Psychedelic Experiences
Johns Hopkins University

PHASE1

Completed

Registry updated 2026-08-14

17

ACTUAL

2024-12-06
2026-07-31
2026-07-31
A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans

NCT07226232

Major Depression
VA Office of Research and Development

PHASE3

Recruiting

Registry updated 2026-08-14

240

ESTIMATED

2026-08-03
2030-12-02
2031-06-30
Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)

NCT06692192

Psilocybin
University of Wisconsin, Madison

PHASE1

Recruiting

Registry updated 2026-08-13

60

ESTIMATED

2025-08-07
2027-12
2027-12
Processing Intergenerational Trauma With Psilocybin-Assisted Therapy

NCT06899165

Psychological Stress · Depression · Anxiety
Rachel Yehuda

PHASE2

Recruiting

Registry updated 2026-08-13

100

ESTIMATED

2026-08-28
2029-05-31
2030-01-02
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

NCT06247839

Major Depressive Disorder
Sharmin Ghaznavi

PHASE3

Recruiting

Registry updated 2026-08-13

20

ESTIMATED

2024-09-10
2028-06-30
2028-06-30
PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)

NCT06853912

Alcohol Use Disorder (AUD) · PTSD
Nathan Brashares Sackett

PHASE2

Active, not recruiting

Registry updated 2026-08-13

40

ESTIMATED

2025-06-01
2026-11-01
2027-06-01
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

NCT06801041

Depression · Anxiety · Cancer
M.D. Anderson Cancer Center

PHASE2

Recruiting

Registry updated 2026-08-12

20

ESTIMATED

2025-05-23
2027-03-31
2029-03-31
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

NCT06706232

Bipolar II Disorder · Depression, Bipolar · Suicidality
The University of Texas Health Science Center, Houston

PHASE2

Recruiting

Registry updated 2026-08-12

10

ESTIMATED

2025-07-07
2027-08
2027-08
Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids

NCT06827054

Hematopoietic and Lymphatic System Neoplasm · Malignant Solid Neoplasm
Roswell Park Cancer Institute

PHASE2

Not yet recruiting

Registry updated 2026-08-12

20

ESTIMATED

2026-09-15
2027-05-05
2027-05-05
A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder

NCT06969170

Generalized Anxiety Disorder (GAD)
Claudio N Soares

PHASE2

Recruiting

Registry updated 2026-08-12

50

ESTIMATED

2025-05-16
2027-12-31
2028-12-30
Psilocybin Recovery Intervention for Stopping Methamphetamine Use

NCT07756736

Methamphetamine Use Disorder · Human Immunodeficiency Virus (HIV)
Nicky Mehtani, MD, MPH

PHASE2

Not yet recruiting

Registry updated 2026-08-11

30

ESTIMATED

2026-11
2029-04
2029-06
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

NCT06656702

Amyotrophic Lateral Sclerosis
Johns Hopkins University

EARLY_PHASE1

Recruiting

Registry updated 2026-08-11

24

ESTIMATED

2025-04-09
2027-01-30
2027-07-01
An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)

NCT06512194

Depression
Charles Raison

PHASE2

Recruiting

Registry updated 2026-08-10

141

ESTIMATED

2025-05-13
2029-05
2029-05
A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression

NCT05711940

Treatment Resistant Depression
COMPASS Pathways

PHASE3

Active, not recruiting

Registry updated 2026-08-10

572

ACTUAL

2023-02-14
2025-11-13
2026-12
Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury

NCT07251491

Spinal Cord Injury · Depression - Major Depressive Disorder · Veteran
James J. Peters Veterans Affairs Medical Center

PHASE1, PHASE2

Recruiting

Registry updated 2026-08-10

30

ESTIMATED

2026-08-06
2028-03-01
2028-03-01
A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression

NCT05624268

Treatment Resistant Depression
COMPASS Pathways

PHASE3

Completed

Registry updated 2026-08-10

258

ACTUAL

2023-01-24
2025-05-28
2026-04-15
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study

NCT06506019

Bipolar Depression
University Health Network, Toronto

PHASE1

Active, not recruiting

Registry updated 2026-08-10

30

ESTIMATED

2024-10-09
2026-09-01
2027-01-01
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

NCT06455293

Parkinson Disease · Depression
Joshua Woolley, MD, PhD

PHASE2

Recruiting

Registry updated 2026-08-07

60

ESTIMATED

2024-08-19
2027-06
2028-06
Open Label Psilocybin Brain Stimulation and Imaging Pilot Study

NCT06835699

Healthy Volunteers
Johns Hopkins University

PHASE1

Completed

Registry updated 2026-08-07

10

ACTUAL

2025-04-18
2026-05-21
2026-05-21
Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder

NCT07406828

Pain Management · Postoperative Pain
Trent Emerick

PHASE1

Not yet recruiting

Registry updated 2026-08-06

70

ESTIMATED

2027-12-31
2029-04
2029-08
Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism

NCT06731621

Treatment Resistant Depression · Autism Spectrum Disorder
Centre for Addiction and Mental Health

PHASE1

Active, not recruiting

Registry updated 2026-08-06

20

ESTIMATED

2024-11-01
2026-12
2026-12
An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy

NCT06233344

Mental Health
University of Southern California

PHASE2

Recruiting

Registry updated 2026-08-06

40

ESTIMATED

2025-07-30
2027-08
2028-08
Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer

NCT06001749

Opioid-Related Disorders · Pain Management · Pain Management and Care · Advanced Cancer · Advanced Cancers
Yvan Beaussant, MD, MSci

PHASE2

Recruiting

Registry updated 2026-08-05

15

ESTIMATED

2024-09-23
2026-10-01
2026-12-31
Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies

NCT07745569

PTSD · PTSD - Post Traumatic Stress Disorder · Major Depression · Suicidality
University of New Mexico

PHASE2

Not yet recruiting

Registry updated 2026-08-04

150

ESTIMATED

2026-08-31
2030-06-30
2030-06-30
Psilocybin as a Treatment for Chronic Pain in Smokers

NCT07118332

Smokers With Chronic Pain
Yale University

EARLY_PHASE1

Recruiting

Registry updated 2026-08-03

10

ESTIMATED

2026-07-06
2027-10-01
2027-12-01
A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression

NCT07336238

Anxiety · Depression · Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm
University of Washington

PHASE2

Active, not recruiting

Registry updated 2026-07-31

18

ESTIMATED

2026-05-19
2026-12-01
2027-05-01
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression

NCT07737990

Treatment-resistant Depression (TRD)
Joshua Rosenblat

NA

Enrolling by invitation

Registry updated 2026-07-30

65

ESTIMATED

2026-07-01
2029-12-31
2030-06-30
Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress Disorder

NCT07737054

Post-Traumatic Stress Disorder, PTSD
Tel-Aviv Sourasky Medical Center

EARLY_PHASE1

Recruiting

Registry updated 2026-07-30

13

ESTIMATED

2025-07-22
2026-12-01
2026-12-31
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

NCT06512220

Treatment Resistant Depression
Centre for Addiction and Mental Health

PHASE2

Recruiting

Registry updated 2026-07-30

12

ESTIMATED

2025-04-21
2027-04
2027-09
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial

NCT06518720

Treatment Resistant Depression · Chronic Pain
Centre for Addiction and Mental Health

PHASE2

Recruiting

Registry updated 2026-07-30

16

ESTIMATED

2025-04-01
2027-03
2027-12
An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD

NCT07275970

PTSD
Scottsdale Research Institute

PHASE1

Active, not recruiting

Registry updated 2026-07-29

24

ESTIMATED

2026-03-20
2026-07-30
2026-10-01
Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin

NCT05866471

Healthy · Psychedelic Experiences · Vagus Nerve Stimulation
University of Wisconsin, Madison

PHASE1

Recruiting

Registry updated 2026-07-29

108

ESTIMATED

2025-01-27
2027-11
2028-01
Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.

NCT07732166

Healthy Adults
Pontifícia Universidade Católica do Rio de Janeiro

EARLY_PHASE1

Recruiting

Registry updated 2026-07-28

100

ESTIMATED

2026-04-01
2027-08-01
2027-12-01
A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

NCT07347405

Obsessive-Compulsive Disorder
Francisco A Moreno

PHASE1

Recruiting

Registry updated 2026-07-23

30

ESTIMATED

2026-05-18
2028-12-31
2029-01-31
Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

NCT05301608

Healthy
Johns Hopkins University

PHASE1, PHASE2

Recruiting

Registry updated 2026-07-23

30

ESTIMATED

2022-03-03
2026-12-01
2027-01-01
Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND)

NCT05723276

Functional Neurological Disorder
King's College London

NA

Completed

Registry updated 2026-07-23

20

ACTUAL

2024-02-14
2026-04-14
2026-07-07
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)

NCT06308653

Depressive Disorder, Major
Usona Institute

PHASE3

Active, not recruiting

Registry updated 2026-07-23

238

ACTUAL

2024-03-13
2026-01-05
2027-01-30
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety

NCT06820723

Depression · Anxiety · Major Depressive Disorder
Ohio State University

PHASE2

Recruiting

Registry updated 2026-07-23

40

ESTIMATED

2026-08-01
2028-09
2028-11
A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of Psilocybin

NCT07710027

Healthy Controls
Diamond Therapeutics Inc.

PHASE1

Completed

Registry updated 2026-07-17

56

ACTUAL

2021-10-19
2022-03-12
2023-03-12
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

NCT06067737

Opioid Use Disorder
Johns Hopkins University

PHASE2

Recruiting

Registry updated 2026-07-17

90

ESTIMATED

2024-02-08
2028-07
2029-05
Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial

NCT07703722

Major Depressive Disorder · Post-Traumatic Stress Disorder (PTSD)
Khyber Medical University Peshawar

PHASE3

Recruiting

Registry updated 2026-07-14

60

ESTIMATED

2026-04-01
2027-10-22
2027-11-22
Mechanistic Studies of Psilocybin in Headache Disorders

NCT06464367

Migraine
Yale University

EARLY_PHASE1

Recruiting

Registry updated 2026-07-13

50

ESTIMATED

2025-05-19
2027-12-31
2027-12-31
PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial

NCT07063862

Psychological Distress
Bruyère Health Research Institute.

PHASE3

Recruiting

Registry updated 2026-07-10

120

ESTIMATED

2026-01-28
2027-08
2027-09
PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial

NCT04754061

Depression, Anxiety · Distress, Emotional
Ottawa Hospital Research Institute

PHASE1, PHASE2

Active, not recruiting

Registry updated 2026-07-10

20

ESTIMATED

2024-01-08
2026-10-01
2027-01-01
Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain

NCT05265546

Perception Disorders
University of California, Berkeley

PHASE1

Recruiting

Registry updated 2026-07-10

80

ESTIMATED

2024-03-08
2028-12-31
2028-12-31
The Effects of Psilocybin on Social Connectedness

NCT07693153

Loneliness · Grief
Yale University

PHASE1

Not yet recruiting

Registry updated 2026-07-09

51

ESTIMATED

2026-08-31
2031-12-15
2031-12-15
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)

NCT06341426

Major Depressive Disorder · Depression · Treatment-Resistant Depression · Mood Disorders
University Health Network, Toronto

PHASE2

Active, not recruiting

Registry updated 2026-07-09

92

ESTIMATED

2024-02-05
2026-07-28
2026-12-28
Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects

NCT06624137

OCD · Major Depressive Disorder (MDD) · Alcohol Use Disorder (AUD) · Healthy Volunteer · Migraine · PTSD · PTSD - Post Traumatic Stress Disorder · Addiction · Tobacco Use Disorder · Obsessive Compulsive Disorder (OCD) · Opioid Use Disorder
Yale University

Phase not reported

Terminated

Registry updated 2026-07-09

5

ACTUAL

2024-12-12
2026-06-14
2026-06-14
Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder

NCT06810310

Opioid Use Disorder
University of Pennsylvania

PHASE2

Recruiting

Registry updated 2026-07-09

24

ESTIMATED

2025-12-22
2027-05-01
2027-05-01
Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation

NCT04161066

Opioid Use Disorder
University of Wisconsin, Madison

PHASE1

Recruiting

Registry updated 2026-07-07

10

ESTIMATED

2021-01-13
2026-12
2026-12
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

NCT06160284

Opioid Use Disorder
Yale University

PHASE1

Recruiting

Registry updated 2026-07-07

12

ESTIMATED

2025-05-28
2027-01
2027-01
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms

NCT07638553

Alcohol Use Disorder · Depressive Sympotoms · Psilocybin
Centre Hospitalier Universitaire de Nīmes

PHASE3

Recruiting

Registry updated 2026-07-01

172

ESTIMATED

2026-06-30
2030-06
2030-06
A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)

NCT06902974

Post Traumatic Stress Disorder · PTSD
Sunstone Medical

PHASE2

Recruiting

Registry updated 2026-07-01

70

ESTIMATED

2026-05-23
2027-11
2028-05
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

NCT05452772

Tobacco Use Disorder
Johns Hopkins University

PHASE2

Recruiting

Registry updated 2026-06-29

66

ESTIMATED

2023-11-01
2026-12
2027-05
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects

NCT06884514

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2026-06-25

24

ACTUAL

2025-04-03
2026-05-13
2026-05-28
A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)

NCT07104916

Post Traumatic Stress Disorder · Depression - Major Depressive Disorder
Anthony P King

PHASE2

Recruiting

Registry updated 2026-06-25

30

ESTIMATED

2026-07-01
2029-09
2029-12
Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial

NCT07048743

Caregiver Distress
University Health Network, Toronto

PHASE2

Recruiting

Registry updated 2026-06-23

15

ESTIMATED

2025-07-16
2027-12-02
2027-12-02
Psilocybin-Assisted Therapy for Prolonged Grief

NCT06724289

Prolonged Grief Disorder
University of Virginia

EARLY_PHASE1

Recruiting

Registry updated 2026-06-23

12

ESTIMATED

2026-03-24
2027-08
2027-08
Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy

NCT06407635

Post Traumatic Stress Disorder
Johns Hopkins University

PHASE1

Active, not recruiting

Registry updated 2026-06-22

20

ESTIMATED

2024-06-07
2026-03-09
2027-05
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial

NCT06416085

Advanced Cancer · Stage IV Solid Tumor Cancer · Stage IV Sarcoma of Bone · Stage IV Lymphoma · Stage IV Melanoma · Endocrine Cancer
University Health Network, Toronto

PHASE2

Active, not recruiting

Registry updated 2026-06-22

15

ESTIMATED

2024-06-06
2026-12-15
2026-12-15
The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function

NCT07079852

Healthy
Manoj Doss

PHASE1, PHASE2

Not yet recruiting

Registry updated 2026-06-15

48

ESTIMATED

2026-09
2028-08
2028-08
Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling

NCT05698511

Psychedelic Experiences · Neuroimaging · Healthy Volunteers
Robin Carhart-Harris, PhD, MA

PHASE1

Active, not recruiting

Registry updated 2026-06-05

12

ESTIMATED

2023-07-31
2026-01-30
2027-01-30
Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study

NCT05370911

Obsessive-Compulsive Disorder
Yale University

PHASE1

Active, not recruiting

Registry updated 2026-06-04

28

ACTUAL

2023-07-20
2026-02-17
2027-02
2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers

NCT06626139

Healthy Participants With Lower-than-average Mental Well-being
Robin Carhart-Harris, PhD, MA

PHASE2

Recruiting

Registry updated 2026-06-04

120

ESTIMATED

2024-10-20
2027-11-30
2028-11-30
Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial

NCT06230757

Major Depressive Disorder · Anhedonia · Treatment Resistant Depression
University of Colorado, Denver

PHASE2

Completed

Registry updated 2026-05-22

20

ACTUAL

2024-07-08
2026-05-08
2026-05-08
Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

NCT07506395

PTSD
University of New Mexico

PHASE1

Recruiting

Registry updated 2026-05-22

36

ESTIMATED

2026-05-01
2027-05-01
2028-05-01
A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression

NCT07582120

Depression
Washington University School of Medicine

PHASE2

Not yet recruiting

Registry updated 2026-05-20

50

ESTIMATED

2026-06
2031-06
2031-12
Psilocybin-assisted Cognitive Behavioral Therapy for Depression

NCT05227612

Major Depressive Disorder
University of California, Los Angeles

PHASE1

Completed

Registry updated 2026-05-19

16

ACTUAL

2023-06-27
2025-09-12
2025-09-12
Psilocybin-facilitated Treatment for Cocaine Use

NCT02037126

Cocaine-Related Disorders
University of Alabama at Birmingham

PHASE2

Completed

Registry updated 2026-05-18

40

ACTUAL

2015-05
2024-05
2024-05
Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)

NCT07216404

Lung Non-Small Cell Carcinoma · Unipolar Depression
Alan Davis

PHASE2

Recruiting

Registry updated 2026-05-14

10

ESTIMATED

2026-01-01
2027-10-31
2027-10-31
Psilocybin for Treatment of Obsessive Compulsive Disorder

NCT06992999

Obsessive - Compulsive Disorder
Francisco A Moreno

PHASE1, PHASE2

Not yet recruiting

Registry updated 2026-05-12

20

ESTIMATED

2026-09-08
2028-12
2028-12
Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based Sample

NCT05322954

Methamphetamine Use Disorder · Substance-Related Disorders · Chemically-Induced Disorders · Substance Use Disorders · Stimulant-Use Disorder
University of Wisconsin, Madison

PHASE1

Terminated

Registry updated 2026-05-12

5

ACTUAL

2023-03-03
2024-03-07
2024-03-07
The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.

NCT06782724

COPD (Chronic Obstructive Pulmonary Disease) · ALS (Amyotrophic Lateral Sclerosis) · MS (Multiple Sclerosis) · Major Depressive Disorder (MDD) · Atypical Parkinson Disease
University Medical Center Groningen

PHASE2

Recruiting

Registry updated 2026-05-08

108

ESTIMATED

2025-07-01
2027-01-01
2028-01-01
Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial

NCT05710237

Treatment-resistant Depression
Centre for Addiction and Mental Health

PHASE2

Completed

Registry updated 2026-05-07

41

ACTUAL

2023-07-01
2026-04-14
2026-04-14
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer

NCT05947383

Cancer · Major Depressive Disorder
Sunstone Medical

PHASE2

Active, not recruiting

Registry updated 2026-05-06

56

ESTIMATED

2023-10-23
2027-04-30
2027-11-01
Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study

NCT06303739

Refractory Depression · Treatment Resistant Depression
University of North Carolina, Chapel Hill

PHASE3

Active, not recruiting

Registry updated 2026-05-06

20

ACTUAL

2024-04-19
2026-04-09
2027-03-26
A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder

NCT07479550

Major Depression
Stanford University

PHASE2

Not yet recruiting

Registry updated 2026-05-06

10

ESTIMATED

2026-07
2027-07
2027-08
A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control

NCT04353921

Major Depressive Disorder
Usona Institute

Phase not reported

Terminated

Registry updated 2026-05-04

26

ACTUAL

2020-06-30
2022-10-18
2022-10-18
A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression

NCT07565909

Depression · Anxiety
University of Washington

PHASE2

Not yet recruiting

Registry updated 2026-05-04

72

ESTIMATED

2026-06
2027-12
2028-07
Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder

NCT07566104

Depression - Major Depressive Disorder · Psilocybin · Cognitive Behavioral Therapy
University of California, Los Angeles

PHASE2

Not yet recruiting

Registry updated 2026-05-04

30

ESTIMATED

2027-01
2028-12
2028-12
Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)

NCT05883540

Palliative Care · Pain · Anxiety · Depression · Demoralization · Psychological Distress · Quality of Life · Caregiver Burden · Fear of Death · Existential Distress
University Hospital, Basel, Switzerland

PHASE2

Recruiting

Registry updated 2026-04-29

60

ESTIMATED

2024-06-09
2027-09
2028-05
A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back Pain

NCT05351541

Chronic Low-back Pain
Joshua Woolley, MD, PhD

PHASE1, PHASE2

Active, not recruiting

Registry updated 2026-04-29

30

ESTIMATED

2023-12-01
2026-07
2026-09
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

NCT04982796

Amphetamine-Related Disorders
Portland VA Research Foundation, Inc

PHASE1, PHASE2

Active, not recruiting

Registry updated 2026-04-22

30

ESTIMATED

2022-07-07
2026-12-31
2026-12-31
A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)

NCT03866174

Depressive Disorder, Major
Usona Institute

PHASE2

Completed

Registry updated 2026-04-22

347

ACTUAL

2020-01-23
2022-06-28
2022-06-28
Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy

NCT07373535

Treatment-Resistant Major Depressive Disorder
Kyle Greenway

PHASE2

Not yet recruiting

Registry updated 2026-04-22

16

ESTIMATED

2026-05
2028-07
2028-12
CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial

NCT06319378

MDD
Section for Affective Disorders; Northern Stockholm Psychiatry

PHASE2

Recruiting

Registry updated 2026-04-13

100

ESTIMATED

2024-04-19
2026-12
2026-12
Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder

NCT06102434

Cocaine Use Disorder
University of California, Los Angeles

EARLY_PHASE1

Suspended

Registry updated 2026-04-07

10

ESTIMATED

2029-02-01
2029-05
2029-06
Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants

NCT06180759

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2026-04-02

17

ACTUAL

2025-01-23
2025-09-29
2025-11-06
Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression

NCT06072898

Depressive Disorder · Major Depressive Disorder
Sunnybrook Health Sciences Centre

PHASE2

Recruiting

Registry updated 2026-03-30

50

ESTIMATED

2025-05-28
2028-05
2029-05
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder

NCT07499583

Treatment Resistant Depression · Substance Use Disorders
Indiana University

PHASE1, PHASE2

Not yet recruiting

Registry updated 2026-03-30

50

ESTIMATED

2026-08-01
2031-01-01
2031-02-28
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression

NCT06898606

Depressive Disorder
Federal University of Latin American Integration

PHASE1, PHASE2

Recruiting

Registry updated 2026-03-27

24

ESTIMATED

2024-09-05
2026-08-20
2026-11-20
The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.

NCT05416229

Alcohol Use Disorder
Anders Fink-Jensen, MD, DMSci

PHASE2

Completed

Registry updated 2026-03-24

60

ACTUAL

2023-09-01
2025-12-22
2025-12-22
Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial

NCT07490353

Depression - Major Depressive Disorder · Anhedonia
Medical University of Vienna

PHASE1

Recruiting

Registry updated 2026-03-24

85

ESTIMATED

2025-11-01
2028-05-31
2028-05-31
Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies

NCT07484906

Suicidal Ideation
University of New Mexico

PHASE2

Withdrawn

Registry updated 2026-03-20

0

ACTUAL

2026-05-01
2029-08-31
2029-08-31
Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder

NCT06660381

Cannabis Use Disorder
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-03-18

12

ESTIMATED

2024-11-08
2026-11
2026-12
Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study

NCT06818994

Demoralization · Safety
Gustavo Vazquez

PHASE1

Recruiting

Registry updated 2026-03-18

15

ESTIMATED

2026-04-01
2027-06-01
2027-06-01
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

NCT04620759

Major Depressive Disorder · Alcohol Use Disorder
Johns Hopkins University

PHASE2

Active, not recruiting

Registry updated 2026-03-13

90

ESTIMATED

2021-04-14
2026-03-02
2027-03-30
Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health

NCT05227742

Demoralization
University of Alabama at Birmingham

EARLY_PHASE1

Withdrawn

Registry updated 2026-03-11

0

ACTUAL

2023-08-15
2026-03
2026-03
Psilocybin-facilitated Treatment for Chronic Pain

NCT05068791

Fibromyalgia, Primary
University of Alabama at Birmingham

EARLY_PHASE1

Recruiting

Registry updated 2026-03-11

30

ESTIMATED

2023-11-01
2026-12-31
2026-12-31
Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study

NCT06442423

Transdiagnostic · Depression - Major Depressive Disorder · Anxiety · PTSD Symptoms · PTSD · Substance Use · Substance Use Disorder (SUD) · OCD
Yale University

PHASE1

Recruiting

Registry updated 2026-03-11

50

ESTIMATED

2024-10-17
2027-12
2027-12
Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.

NCT06760533

IBS - Irritable Bowel Syndrome
NYU Langone Health

EARLY_PHASE1

Not yet recruiting

Registry updated 2026-03-05

10

ESTIMATED

2026-08
2026-12
2026-12
Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial

NCT05554094

PTSD · Stress Disorders, Traumatic · Stress Disorders, Post-Traumatic · Trauma and Stressor Related Disorders · Mental Disorder
Ohio State University

PHASE2

Active, not recruiting

Registry updated 2026-03-04

15

ESTIMATED

2023-01-01
2025-12-31
2026-07-31
A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.

NCT07072728

Adjustment Disorder · Adjustment Disorder With Anxious Mood · Cancer · Cancer Cachexia · Cancer of Endometrium · Cancer of Kidney · Cancer of Prostate · Cancer of the Breast · Cancer of Stomach · Cancer Melanoma Skin · Cancer Pancreas
Psyence Australia Pty Ltd

PHASE2

Recruiting

Registry updated 2026-03-03

87

ESTIMATED

2025-10-01
2026-12-30
2027-07-30
Study of Psilocybin for Anorexia in Young Adults

NCT06399263

Anorexia Nervosa
Marissa Raymond-Flesch, MD, MPH

PHASE2

Recruiting

Registry updated 2026-03-03

40

ESTIMATED

2024-11-18
2029-11
2029-11
The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.

NCT07433452

Healthy Participants · Placebo - Control · Psilocybin
Gabriella Gobbi

PHASE1

Not yet recruiting

Registry updated 2026-02-25

50

ESTIMATED

2026-09-01
2028-09-01
2029-09-01
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

NCT06005662

Opioid Use Disorder
Johns Hopkins University

PHASE2

Withdrawn

Registry updated 2026-02-23

0

ACTUAL

2027-04
2028-07
2028-07
Investigation of Psychedelic Effects in Psychoactive Substances

NCT06772753

Psychedelic Effects in Healthy Volunteers
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-02-23

50

ESTIMATED

2025-02-05
2027-06
2027-12
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH Study

NCT04950608

Hospice · Psilocybin · Demoralization · Terminal Illness · Cancer-related Problem/Condition · Psychotherapy · Terminal Cancer · Cancer Terminal
Yvan Beaussant, MD, MSci

PHASE2

Completed

Registry updated 2026-02-17

15

ACTUAL

2022-03-09
2024-07-27
2025-12-31
A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

NCT07050368

Healthy Volunteer
MycoMedica Life Sciences PBC

PHASE1

Completed

Registry updated 2026-02-13

20

ACTUAL

2025-07-28
2026-01-13
2026-01-13
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

NCT07053917

Stroke · Chronic Stroke · Intracerebral Haemorrhage · Intracerebral Haemorrhage (ICH) · Intracerebral Hemorrhage Basal Ganglia · Ischemic Stroke · Ischemic Stroke and Hemorrhagic Stroke · Hemiparesis After Stroke · Hemiplegia Following Ischemic Stroke · Hemiplegia and Hemiparesis · Hemiplegia and/or Hemiparesis Following Stroke · Middle Cerebral Artery Stroke
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-02-13

20

ESTIMATED

2026-02-09
2027-02
2027-03
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial

NCT07405606

Major Depressive Disorder (MDD) · Alcohol Use Disorder (AUD)
Centre for Addiction and Mental Health

PHASE2

Not yet recruiting

Registry updated 2026-02-12

30

ESTIMATED

2026-03
2028-03
2028-06
Psilocybin-Assisted Cognitive Behavioral Therapy for Depression

NCT07281352

Major Depressive Diorder
University of California, Los Angeles

PHASE1, PHASE2

Recruiting

Registry updated 2026-02-12

50

ESTIMATED

2026-01-05
2027-11-30
2027-11-30
Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers

NCT07079930

Healthy Volunteers
Hadassah Medical Organization

PHASE1

Recruiting

Registry updated 2026-02-05

10

ESTIMATED

2025-12-11
2026-11
2027-02
A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design

NCT06206265

Irritable Bowel Syndrome
TRYP Therapeutics

PHASE2

Active, not recruiting

Registry updated 2026-02-05

14

ACTUAL

2024-01-17
2026-03-01
2026-03-01
Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot Study

NCT07391332

Gambling Disorder
Nantes University Hospital

PHASE2

Not yet recruiting

Registry updated 2026-02-05

30

ESTIMATED

2026-04-01
2029-01-01
2029-01-01
A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment

NCT06796062

Opioid Use Disorder
NYU Langone Health

PHASE2

Recruiting

Registry updated 2026-01-23

480

ESTIMATED

2025-12-17
2029-02
2029-02
The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma

NCT06888128

PTSD
Baylor College of Medicine

PHASE2

Recruiting

Registry updated 2026-01-22

15

ESTIMATED

2025-01-30
2026-12-15
2026-12-15
Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb Pain

NCT05224336

Phantom Limb Pain
University of California, San Diego

PHASE1

Completed

Registry updated 2026-01-09

10

ACTUAL

2022-10-03
2024-03-07
2024-03-07
Microdosing Psychedelics to Improve Mood

NCT05259943

Major Depressive Disorder
Rotem Petranker

PHASE2

Completed

Registry updated 2025-12-30

39

ACTUAL

2023-07-15
2024-12-21
2025-02-01
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

NCT05220410

Treatment Resistant Depression · Suicidal Ideation
Sheppard Pratt Health System

PHASE2

Completed

Registry updated 2025-12-24

20

ACTUAL

2022-03-28
2025-05-12
2025-05-12
An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder

NCT05399498

Borderline Personality Disorder · Major Depressive Disorder
University of Chicago

PHASE2

Completed

Registry updated 2025-12-23

9

ACTUAL

2023-11-01
2025-12-01
2025-12-01
Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter

NCT07296328

Stuttering
NYU Langone Health

PHASE2

Not yet recruiting

Registry updated 2025-12-22

25

ESTIMATED

2026-01-15
2027-04-01
2027-04-01
Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study

NCT06798636

Self Harm
Imperial College London

EARLY_PHASE1

Recruiting

Registry updated 2025-12-05

30

ESTIMATED

2025-10-01
2026-08-31
2026-10-31
Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study

NCT05585229

Opioid Dependence · Chronic Pain
University of British Columbia

PHASE2

Recruiting

Registry updated 2025-12-04

10

ESTIMATED

2025-10-27
2026-08-31
2026-08-31
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer

NCT05398484

Advanced Cancer
NYU Langone Health

PHASE2, PHASE3

Recruiting

Registry updated 2025-12-04

200

ESTIMATED

2023-05-24
2027-01-01
2027-01-01
Psilocybin vs Ketamine for Alcohol Use Disorder

NCT06405607

Alcohol Use Disorder · Alcohol Dependence · Alcohol Abuse
University of Iowa

PHASE2

Recruiting

Registry updated 2025-11-28

80

ESTIMATED

2025-06-12
2028-04
2028-04
Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers.

NCT06815653

Healthy
University College, London

PHASE1

Recruiting

Registry updated 2025-11-26

40

ESTIMATED

2025-03-01
2026-03
2026-12
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder

NCT06132178

Treatment Resistant Depression · MDD · Major Depressive Disorder · Recurrent Depression · Depression
University of Texas at Austin

PHASE2

Recruiting

Registry updated 2025-11-26

100

ESTIMATED

2025-01-10
2029-12-31
2030-12-31
Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life

NCT05403086

Demoralization
Charles S. Grob, M.D.

PHASE2

Recruiting

Registry updated 2025-11-25

100

ESTIMATED

2025-01-19
2026-12-31
2027-12-31
Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans

NCT06081179

Healthy
University of Zurich

PHASE1

Completed

Registry updated 2025-11-19

122

ACTUAL

2023-10-24
2025-09-22
2025-09-22
A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression

NCT07183748

Treatment Resistant Depression
Beersheva Mental Health Center

PHASE2

Recruiting

Registry updated 2025-11-19

20

ESTIMATED

2025-12-01
2027-06-01
2028-06-01
Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.

NCT04882839

Obsessive-compulsive Disorder
Beersheva Mental Health Center

PHASE2

Recruiting

Registry updated 2025-11-19

15

ESTIMATED

2024-11-25
2026-06-01
2027-06-01
Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder

NCT05421065

Alcohol Use Disorder
Peggy C Nopoulos

PHASE2

Active, not recruiting

Registry updated 2025-11-17

20

ESTIMATED

2024-02-02
2025-08-30
2026-09
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

NCT03554174

Major Depressive Disorder
Yale University

PHASE1

Active, not recruiting

Registry updated 2025-11-05

18

ESTIMATED

2018-02-27
2021-07-08
2026-09
A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer

NCT05847686

Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm
University of Washington

PHASE1, PHASE2

Completed

Registry updated 2025-11-05

55

ACTUAL

2023-06-27
2024-04-08
2024-10-17
Precision Functional Brain Mapping to Understand the Mechanisms of Psilocybin

NCT04501653

Psilocybin
Washington University School of Medicine

EARLY_PHASE1

Completed

Registry updated 2025-10-31

11

ACTUAL

2021-06-01
2023-03-19
2023-03-19
A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?

NCT06786325

Opioid Use Disorder
Anna Rose Childress, Ph.D.

PHASE2

Recruiting

Registry updated 2025-10-29

36

ESTIMATED

2025-10-07
2027-06
2027-10
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

NCT06367738

Aging
University of California, Berkeley

PHASE1

Recruiting

Registry updated 2025-10-21

40

ESTIMATED

2025-11
2026-12-30
2027-12-30
A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer

NCT06644170

Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm
University of Washington

PHASE1

Completed

Registry updated 2025-10-14

15

ACTUAL

2024-11-19
2025-09-30
2025-09-30
A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine

NCT06899594

Methamphetamine Use Disorder
Kevin Murnane

EARLY_PHASE1

Recruiting

Registry updated 2025-10-07

20

ESTIMATED

2025-04-04
2027-03
2027-03
Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment

NCT07164287

Major Depressive Disorder (MDD) · Anxiety Disorders · Substance Use Disorder (SUD) · PTSD - Post Traumatic Stress Disorder
University Hospital, Geneva

Phase not reported

Active, not recruiting

Registry updated 2025-10-02

376

ESTIMATED

2020-06-01
2025-04-30
2025-09-30
Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism

NCT07189988

Alcohol Use Disorder
Healing Advocacy Fund

Phase not reported

Active, not recruiting

Registry updated 2025-09-24

20

ACTUAL

2025-03-05
2026-06-10
2026-08-05
The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.

NCT06368492

Fibromyalgia
Maastricht University

NA

Recruiting

Registry updated 2025-09-15

35

ESTIMATED

2024-05-03
2025-12
2025-12
Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.

NCT07164755

Depression - Major Depressive Disorder
King's College London

Phase not reported

Active, not recruiting

Registry updated 2025-09-10

46

ACTUAL

2021-06-21
2026-09
2026-09
Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial

NCT06746441

Major Depressive Disorder
Khyber Medical University Peshawar

PHASE2

Completed

Registry updated 2025-09-02

60

ACTUAL

2024-12-01
2025-06-01
2025-07-30
Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures

NCT06647056

Psychogenic Nonepileptic Seizures · Psilocybin
Centre Hospitalier Universitaire de Nīmes

NA

Completed

Registry updated 2025-08-21

4

ACTUAL

2024-12-19
2025-01-03
2025-05-22
Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression: a Pilot Clinical Neuroimaging Study

NCT06650800

Depressive Disorder · Depressive Disorder, Treatment-Resistant · Hallucinogens · Reinforcement, Psychology
Centre Hospitalier Universitaire de Nīmes

NA

Completed

Registry updated 2025-08-20

10

ACTUAL

2024-11-19
2025-03-26
2025-06-26
Effects of Psilocybin in Post-Treatment Lyme Disease

NCT05305105

Post-Treatment Lyme Disease · Chronic Lyme Disease · Lyme Disease, Chronic
Johns Hopkins University

PHASE1

Completed

Registry updated 2025-08-20

20

ACTUAL

2022-07-01
2024-10-26
2025-04-07
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

NCT05733546

Major Depressive Disorder
COMPASS Pathways

PHASE2

Active, not recruiting

Registry updated 2025-08-19

102

ACTUAL

2023-01-30
2025-09
2025-09
Modulation of Serotonin Pathways Using Psilocybin in Adults With and Without Autism Spectrum Disorder (ASD)

NCT05651126

Autism Spectrum Disorder
King's College London

NA

Completed

Registry updated 2025-07-28

67

ACTUAL

2022-12-12
2024-08-23
2024-08-23
The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)

NCT05506982

Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
Emory University

PHASE1

Completed

Registry updated 2025-07-23

11

ACTUAL

2022-11-01
2024-04-25
2025-01-24
Visual Surround Suppression and Perceptual Expectation Under Psilocybin

NCT04424225

Perception Disturbance · Visual Suppression · Psychedelic Experiences
University of Minnesota

PHASE1

Terminated

Registry updated 2025-06-27

10

ACTUAL

2021-08-30
2023-09-01
2023-09-01
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

NCT05312151

Post Traumatic Stress Disorder
COMPASS Pathways

PHASE2

Completed

Registry updated 2025-06-13

22

ACTUAL

2022-06-10
2024-02-12
2024-02-12
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Participants

NCT06643637

Healthy Volunteers
MycoMedica Life Sciences PBC

PHASE1

Completed

Registry updated 2025-06-12

16

ACTUAL

2024-11-08
2025-03-12
2025-03-12
Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults

NCT05317689

Healthy
University of California, San Francisco

PHASE1

Active, not recruiting

Registry updated 2025-06-10

20

ESTIMATED

2022-05-26
2025-01-16
2025-07
Psilocybin With Intracranial Neural Sensing

NCT06919640

Chronic Pain
Joshua Woolley, MD, PhD

PHASE1

Enrolling by invitation

Registry updated 2025-06-06

20

ESTIMATED

2025-06-01
2028-04-30
2028-04-30
Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study

NCT06372197

Depression
Matthew Hicks

NA

Completed

Registry updated 2025-06-05

20

ACTUAL

2024-08-01
2025-05-14
2025-05-14
Optimizing Microdosing and Meditation

NCT06560658

Meditation · Microdosing
National University of Natural Medicine

NA

Withdrawn

Registry updated 2025-06-05

0

ACTUAL

2024-10-01
2025-10-01
2025-11-01
Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)

NCT06796361

Healthy
University Hospital, Basel, Switzerland

PHASE1

Recruiting

Registry updated 2025-05-28

16

ESTIMATED

2025-04-21
2026-08
2026-08
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

NCT01943994

Nicotine Dependence
Johns Hopkins University

NA

Completed

Registry updated 2025-05-25

82

ACTUAL

2008-09
2023-05-01
2023-11-14
Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot Phase

NCT05592379

Healthy · Psychedelic Experiences · Sleep
University of Wisconsin, Madison

PHASE1

Completed

Registry updated 2025-05-16

6

ACTUAL

2023-11-07
2025-02-19
2025-02-19
Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder

NCT06592833

Major Depressive Disorder
Icahn School of Medicine at Mount Sinai

PHASE2

Recruiting

Registry updated 2025-05-14

60

ESTIMATED

2025-02-25
2028-03-01
2028-03-01
A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With Fibromyalgia

NCT05128162

Fibromyalgia
Kevin Boehnke

PHASE2

Completed

Registry updated 2025-04-16

17

ACTUAL

2023-09-27
2024-06-12
2024-06-12
The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training

NCT05570708

Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD
Felix Mueller

NA

Enrolling by invitation

Registry updated 2025-04-14

48

ESTIMATED

2022-10-25
2029-06-01
2029-06-01
Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study).

NCT05695495

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2025-04-11

36

ACTUAL

2024-06-12
2025-02-02
2025-03-04
Psilocybin-assisted Interpersonal Therapy for Depression

NCT05581797

Depressive Disorder, Treatment-Resistant
University of Otago

NA

Completed

Registry updated 2025-04-09

5

ACTUAL

2023-03-15
2024-05-06
2024-06-04
Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN

NCT06731335

Chronic Neuropathic Pain · Pain Management
Unity Health Toronto

PHASE2

Recruiting

Registry updated 2025-03-30

30

ESTIMATED

2025-03-05
2026-08
2026-12
Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)

NCT06899334

Healthy
University Hospital, Basel, Switzerland

PHASE1

Recruiting

Registry updated 2025-03-27

24

ESTIMATED

2025-04-01
2026-08-01
2026-08-01
Molecular Imaging Study of Harmine/DMT: a Basic Research Approach

NCT06252506

Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine
Insel Gruppe AG, University Hospital Bern

PHASE1

Completed

Registry updated 2025-03-19

17

ACTUAL

2024-01-22
2025-02-17
2025-03-05
Psilocybin in Alcohol Use Disorder With Comorbid Depression

NCT06235411

Alcohol-Related Disorders · Depressive Disorder · Addiction
Centre Hospitalier Universitaire de Nīmes

NA

Completed

Registry updated 2025-03-19

30

ACTUAL

2024-02-05
2024-11-19
2025-01-09
A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout

NCT05163496

Burnout, Caregiver · Burnout, Professional · COVID-19 · Depression · Post Traumatic Stress Disorder · Moral Injury
University of Washington

PHASE3

Completed

Registry updated 2025-03-18

30

ACTUAL

2022-03-03
2023-12-30
2024-06-30
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

NCT00302744

Anxiety
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

PHASE1, PHASE2

Completed

Registry updated 2025-03-13

12

ACTUAL

2004-04
2008-12
2008-12
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects

NCT05523401

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2025-03-05

24

ACTUAL

2023-08-16
2024-10-20
2024-11-05
A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression

NCT04670081

Treatment-resistant Depression
Central Institute of Mental Health, Mannheim

PHASE2

Completed

Registry updated 2025-01-20

144

ACTUAL

2021-06-10
2024-02-27
2024-12-11
The Neurobiological Effect of 5-HT2AR Modulation

NCT03289949

Basic Science
Gitte Moos Knudsen

PHASE1

Recruiting

Registry updated 2024-12-16

200

ESTIMATED

2017-03-03
2030-06-01
2030-06-01
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

NCT05481736

Anorexia Nervosa
COMPASS Pathways

PHASE2

Completed

Registry updated 2024-12-04

32

ACTUAL

2022-10-12
2024-11-18
2024-11-18
Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.

NCT03356483

Obsessive-Compulsive Disorder
Yale University

PHASE1

Completed

Registry updated 2024-11-20

31

ACTUAL

2018-11-13
2024-07-25
2024-07-25
A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder

NCT05035927

Binge Eating Disorder
TRYP Therapeutics

PHASE2

Completed

Registry updated 2024-11-19

5

ACTUAL

2022-03-16
2024-03-07
2024-06-07
PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related Burnout

NCT05557643

Depression · Burnout, Professional
University of Utah

PHASE1

Completed

Registry updated 2024-11-12

24

ACTUAL

2023-01-02
2024-09-20
2024-09-20
PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)

NCT06258031

Obsessive-Compulsive Disorder
Imperial College London

PHASE1

Completed

Registry updated 2024-11-06

19

ACTUAL

2022-10-28
2024-06-28
2024-07-24
A Registered Clinical Trial of PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study

NCT06666010

Stimulant Use Disorder
Filament Health Corp.

PHASE2

Not yet recruiting

Registry updated 2024-10-30

86

ESTIMATED

2025-01
2028-01
2028-07
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms

NCT03429075

Depressive Disorder, Major
Imperial College London

PHASE2

Completed

Registry updated 2024-10-24

59

ACTUAL

2019-01-07
2020-04-17
2020-10-17
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants

NCT06326606

Healthy Volunteers
MycoMedica Life Sciences PBC

PHASE1

Completed

Registry updated 2024-10-09

24

ACTUAL

2024-03-27
2024-07-08
2024-07-08
The Effects of Psilocybin on Shared Experience in Film Processing

NCT06529939

Disorders of Consciousness · Psychedelic Experiences
Western University, Canada

NA

Unknown status

Registry updated 2024-09-27

30

ESTIMATED

2024-11
2025-09
2025-09
An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder

NCT05065294

Bipolar II Disorder
University of California, San Francisco

PHASE2

Active, not recruiting

Registry updated 2024-09-25

14

ESTIMATED

2022-01-28
2024-08-01
2025-07
Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus

NCT06378229

Treatment Resistant Depression
University Hospital, Ghent

PHASE2

Recruiting

Registry updated 2024-09-19

100

ESTIMATED

2024-05-21
2026-03
2026-12-31
Psilocybin for Treatment of Obsessive Compulsive Disorder

NCT03300947

Obsessive-compulsive Disorder (OCD)
University of Arizona

PHASE1

Completed

Registry updated 2024-08-30

15

ACTUAL

2019-01-02
2023-10-30
2023-12-30
A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)

NCT05646303

Alcohol Use Disorder
Clairvoyant Therapeutics

PHASE2

Unknown status

Registry updated 2024-08-15

128

ESTIMATED

2022-05-02
2024-08-31
2024-12-31
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

NCT04433858

Treatment Resistant Depression
Sheppard Pratt Health System

PHASE2

Active, not recruiting

Registry updated 2024-08-09

27

ACTUAL

2021-03-01
2025-06-01
2026-05-01
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms

NCT06160232

Severe Alcohol Use Disorder
Brugmann University Hospital

PHASE2

Recruiting

Registry updated 2024-08-07

62

ESTIMATED

2024-02-15
2025-12-15
2026-06-15
Psilocybin for the Treatment of Major Depressive Disorder

NCT05675800

Major Depressive Disorder
Washington University School of Medicine

PHASE2

Withdrawn

Registry updated 2024-07-25

0

ACTUAL

2024-01-01
2025-01-01
2025-03-31
Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study

NCT04718792

Alcohol Use Disorder (AUD)
Anders Fink-Jensen, MD, DMSci

PHASE2

Unknown status

Registry updated 2024-07-12

10

ACTUAL

2023-02-09
2024-07-21
2024-07-21
Assessing the Feasibility of a Custom Psychedelic-assisted Group Program on Mental and Physical Health in First Responders

NCT06471959

Psilocybin · Psychotherapy, Group
Empower Research Inc

PHASE1, PHASE2

Unknown status

Registry updated 2024-06-24

32

ESTIMATED

2025-01-01
2025-07-01
2025-09-01
Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion

NCT02243813

Healthy
Johns Hopkins University

PHASE1

Completed

Registry updated 2024-06-18

24

ACTUAL

2015-03
2024-05-31
2024-05-31
Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study

NCT04505189

Anorexia Nervosa
Imperial College London

PHASE1, PHASE2

Completed

Registry updated 2024-06-17

21

ACTUAL

2021-05-28
2023-12-11
2024-06-12
A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder

NCT06444243

Alcohol Use Disorder · Alcohol Dependence · Depression · Anxiety
University of Sydney

PHASE2

Unknown status

Registry updated 2024-06-10

90

ESTIMATED

2024-09
2025-07
2025-12
An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult Patients

NCT05832255

Fragile X Syndrome · Behavior · Cognitive Dysfunction
Nova Mentis Life Science Corp

PHASE2

Suspended

Registry updated 2024-05-08

10

ESTIMATED

2023-03-28
2024-05
2024-05
Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial

NCT05995769

Alcohol Use Disorder · Alcoholism
University of Calgary

PHASE2

Recruiting

Registry updated 2024-05-07

128

ESTIMATED

2024-03-20
2027-10-01
2027-10-01
Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over Study

NCT05384678

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2024-04-25

24

ACTUAL

2022-11-15
2024-03-08
2024-03-13
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study

NCT04630964

Major Depressive Disorder · Depression
Section for Affective Disorders; Northern Stockholm Psychiatry

PHASE2

Completed

Registry updated 2024-04-19

35

ACTUAL

2021-01-01
2023-04-19
2024-04-18
A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer

NCT04522804

Cancer
University of Utah

EARLY_PHASE1

Completed

Registry updated 2024-03-20

12

ACTUAL

2021-10-04
2022-06-11
2022-12-16
Repeat Dosing of Psilocybin in Headache Disorders

NCT04218539

Migraine Headache
Yale University

PHASE1

Completed

Registry updated 2024-02-09

18

ACTUAL

2021-08-10
2023-11-05
2023-11-05
A Randomized, Double-Blind Study of Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use

NCT05242029

Opioid Use Disorder
Johns Hopkins University

PHASE2

Withdrawn

Registry updated 2024-02-02

0

ACTUAL

2023-12
2024-02
2024-12
Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy Subjects

NCT04227756

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2024-01-24

32

ACTUAL

2020-05-19
2022-09-02
2022-09-02
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

NCT05381974

Treatment-Resistant Major Depressive Disorder
Massachusetts General Hospital

PHASE2

Withdrawn

Registry updated 2024-01-24

0

ACTUAL

2022-09-15
2023-06-01
2023-06-01
Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action

NCT05548075

Fibromyalgia
Imperial College London

Phase not reported

Unknown status

Registry updated 2024-01-19

20

ESTIMATED

2022-08-15
2024-01-10
2024-07-30
Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder

NCT05562973

Post-Traumatic Stress Disorder
Johns Hopkins University

PHASE1

Withdrawn

Registry updated 2024-01-05

0

ACTUAL

2025-01
2025-12
2025-12
Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.

NCT00979693

Anxiety · Stage IV Melanoma
Multidisciplinary Association for Psychedelic Studies

PHASE2

Withdrawn

Registry updated 2023-12-26

0

ACTUAL

2012-01
2013-04
2013-06
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders

NCT02981173

Cluster Headache
Yale University

PHASE1

Completed

Registry updated 2023-12-15

25

ACTUAL

2016-12-05
2022-06-30
2022-10-21
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).

NCT06141876

Post-traumatic Stress Disorder · Depression
Apex Labs Ltd.

PHASE2

Unknown status

Registry updated 2023-11-29

160

ESTIMATED

2023-12-15
2025-06-15
2025-06-15
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

NCT04739865

Treatment Resistant Depression
COMPASS Pathways

PHASE2

Completed

Registry updated 2023-11-09

19

ACTUAL

2020-08-10
2021-10-14
2021-10-14
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II

NCT03806985

Post-Traumatic Headache
Yale University

PHASE1

Terminated

Registry updated 2023-10-12

12

ACTUAL

2019-03-28
2023-06-27
2023-06-27
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study I

NCT03341689

Migraine Headache
Yale University

PHASE1

Completed

Registry updated 2023-10-12

14

ACTUAL

2017-11-01
2021-04-30
2021-10-31
Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence

NCT01534494

Alcohol Dependence
University of New Mexico

PHASE2

Completed

Registry updated 2023-09-26

10

ACTUAL

2012-01
2013-09
2014-03
Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced Meditators

NCT05780216

Healthy Participants
Milan Scheidegger

EARLY_PHASE1

Completed

Registry updated 2023-09-21

40

ACTUAL

2023-02-20
2023-08-05
2023-09-15
Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder

NCT04141501

Alcohol Use Disorder
University of Zurich

PHASE2

Completed

Registry updated 2023-09-21

37

ACTUAL

2020-06-08
2023-03-14
2023-09-14
Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted Conditions

NCT06035900

Side Effect of Drug
Lobe Sciences Ltd.

PHASE1

Completed

Registry updated 2023-09-13

10

ACTUAL

2023-06-21
2023-07-30
2023-07-30
A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin Pharmacokinetics

NCT05478278

QTc Interval · Pharmacokinetics
Usona Institute

PHASE1

Completed

Registry updated 2023-08-15

60

ACTUAL

2022-06-22
2023-08-09
2023-08-09
The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study

NCT05029466

Treatment Resistant Depression
Brain and Cognition Discovery Foundation

PHASE2

Completed

Registry updated 2023-07-27

30

ACTUAL

2021-11-19
2023-07-22
2023-07-22
An Open Label Pragmatic Feasibility Study on a Resilience Focused Community of Practice Program With Psilocybin-assisted Therapy (PaT) for End-of-Life Patients.

NCT05958758

End of Life
The Roots to Thrive Society for Psychedelic Therapy

EARLY_PHASE1

Unknown status

Registry updated 2023-07-25

64

ESTIMATED

2023-09-01
2025-04-30
2025-10-31
Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)

NCT05594667

Depression · Major Depressive Disorder · Mild Depression · Moderate Depression · Depressive Disorder
Cybin Therapeutics Inc.

PHASE2

Withdrawn

Registry updated 2023-07-06

0

ACTUAL

2023-01-01
2023-03-14
2023-03-14
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

NCT05243329

Treatment Resistant Disorders · Post Traumatic Stress Disorder
Halucenex Life Sciences Inc.

PHASE2

Unknown status

Registry updated 2023-06-29

20

ESTIMATED

2022-10-03
2023-10-30
2023-12-30
Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans

NCT05876481

PTSD
Combat Stress

PHASE2

Unknown status

Registry updated 2023-05-25

8

ESTIMATED

2023-06
2025-07
2025-08
Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult Volunteers

NCT04842045

Psychedelic Experiences · Amnesia
University of Wisconsin, Madison

PHASE1

Completed

Registry updated 2023-05-19

8

ACTUAL

2021-05-21
2022-11-17
2022-11-17
A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin

NCT05467761

Healthy
University of Wisconsin, Madison

PHASE1

Withdrawn

Registry updated 2023-05-15

0

ACTUAL

2023-06
2024-03
2024-03
Effects of Psilocybin in Anorexia Nervosa

NCT04052568

Anorexia Nervosa
Johns Hopkins University

PHASE1

Completed

Registry updated 2023-05-06

22

ACTUAL

2019-08-26
2022-01-05
2023-04-20
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

NCT03775200

Treatment Resistant Depression
COMPASS Pathways

PHASE2

Completed

Registry updated 2023-04-24

233

ACTUAL

2019-03-01
2021-07-30
2021-09-27
Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness

NCT04849013

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2023-03-29

16

ACTUAL

2021-08-11
2023-03-27
2023-03-27
Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding Study

NCT05252598

Mood Disturbance · Mood Change · Sleep Disturbance · Drug Effect · Psychedelic Experiences · Health, Subjective · Psilocin Toxicity · Psilocybin Toxicity · Psilocybin Causing Adverse Effects in Therapeutic Use · Anxiety
Optimi Health Corporation

EARLY_PHASE1

Withdrawn

Registry updated 2023-03-20

0

ACTUAL

2023-01
2023-08
2023-12
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

NCT04656301

Body Dysmorphic Disorders
New York State Psychiatric Institute

PHASE2

Completed

Registry updated 2023-03-13

12

ACTUAL

2021-02-26
2022-11-02
2022-11-02
SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression

NCT05601648

Major Depressive Disorder · Anhedonia
Washington University School of Medicine

PHASE2

Withdrawn

Registry updated 2023-01-30

0

ACTUAL

2023-07-01
2025-01-01
2025-07-01
Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder

NCT04410913

Alcohol Use Disorder
Keith Heinzerling

PHASE2

Active, not recruiting

Registry updated 2023-01-17

20

ACTUAL

2021-02-18
2023-02
2023-02
NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System.

NCT05042466

Trauma, Nervous System
NWTraumatherapies

PHASE1

Unknown status

Registry updated 2022-11-16

30

ESTIMATED

2023-09-03
2025-08-30
2025-10-03
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

NCT02061293

Alcohol Dependence
NYU Langone Health

PHASE2

Completed

Registry updated 2022-11-08

95

ACTUAL

2014-06
2021-07-30
2021-07-30
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

NCT04433845

Treatment Resistant Depression
Sheppard Pratt Health System

PHASE2

Unknown status

Registry updated 2022-10-25

15

ACTUAL

2021-03-01
2023-01-15
2023-04-15
An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

NCT04905121

Short Lasting Unilateral Neuralgiform Headache Attacks
Beckley Psytech Limited

PHASE1

Terminated

Registry updated 2022-10-12

4

ACTUAL

2021-08-11
2022-04-22
2022-04-22
Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)

NCT04519957

Treatment Resistant Depression
COMPASS Pathways

Phase not reported

Completed

Registry updated 2022-09-22

66

ACTUAL

2020-07-20
2022-08-11
2022-08-11
Prophylactic Effects of Psilocybin on Chronic Cluster Headache: an Open-label Clinical Trial and Neuroimaging Study

NCT04280055

Cluster Headache
Gitte Moos Knudsen

PHASE1, PHASE2

Terminated

Registry updated 2022-08-10

10

ACTUAL

2020-01-21
2020-11-01
2022-06-01
Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

NCT04661514

Anorexia Nervosa
University of California, San Diego

PHASE2

Completed

Registry updated 2022-07-25

16

ACTUAL

2021-05-01
2022-03-10
2022-06-10
Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults

NCT04989972

Anxiety and Depression
Wake Network, Inc.

PHASE2

Withdrawn

Registry updated 2022-06-30

0

ACTUAL

2022-09-15
2023-06-20
2023-08-31
Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant Depression

NCT05383313

Treatment Resistant Depression
National Institute of Mental Health, Czech Republic

PHASE2

Unknown status

Registry updated 2022-05-20

60

ESTIMATED

2021-05-01
2025-04-30
2025-04-30
Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy in Major Depression

NCT03715127

Depressive Disorder, Major
University of Zurich

PHASE2

Completed

Registry updated 2022-04-29

55

ACTUAL

2019-03-11
2021-10-12
2022-04-12
A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion

NCT02421263

Religious or Spiritual Problem
NYU Langone Health

PHASE1

Completed

Registry updated 2022-02-14

12

ACTUAL

2015-04
2020-06-05
2020-06-05
LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study

NCT03153579

Patients · Anxiety Disorders
University Hospital, Basel, Switzerland

PHASE2

Completed

Registry updated 2021-12-22

46

ACTUAL

2017-06-23
2021-12-15
2021-12-15
Double-blind Placebo-controlled Naturalistic Study of Microdosing With Psilocybin: Effects on Brain Activity, Behavior, Cognition, Creativity, and Mental Health

NCT05160220

Cognitive Change · Creativity · Mood Change · Sleep
National Council of Scientific and Technical Research, Argentina

NA

Completed

Registry updated 2021-12-16

34

ACTUAL

2021-01-20
2021-06-30
2021-10-01
Effects of Psilocybin in Major Depressive Disorder

NCT03181529

Major Depressive Disorder
Johns Hopkins University

PHASE2

Completed

Registry updated 2021-12-15

27

ACTUAL

2017-08-10
2020-12-02
2020-12-02
The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder

NCT04593563

Major Depressive Disorder
Maryland Oncology Hematology, PA

PHASE2

Unknown status

Registry updated 2021-10-15

30

ACTUAL

2020-09-01
2022-10
2023-10
Characterization of Altered Waking States of Consciousness in Healthy Humans

NCT03853577

Altered Waking States of Consciousness in Healthy Humans
University of Zurich

NA

Completed

Registry updated 2021-04-29

25

ACTUAL

2020-07-08
2021-04-25
2021-04-25
Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin in a Random-order Placebo-controlled Cross-over Study in Healthy Subjects

NCT03604744

Healthy
University Hospital, Basel, Switzerland

EARLY_PHASE1

Completed

Registry updated 2021-04-27

28

ACTUAL

2019-03-27
2021-04-10
2021-04-15
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

NCT02950467

Distress · Depression · Grief
Joshua Woolley

PHASE1

Completed

Registry updated 2021-01-07

30

ACTUAL

2018-01-05
2019-12-31
2019-12-31
Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy Subjects

NCT03912974

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2020-12-01

27

ACTUAL

2019-07-04
2020-11-26
2020-11-26
Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self

NCT03736980

Healthy
University of Zurich

NA

Completed

Registry updated 2020-11-04

140

ACTUAL

2013-10-01
2018-12-31
2018-12-31
Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients

NCT00957359

Cancer
NYU Langone Health

EARLY_PHASE1

Completed

Registry updated 2020-10-20

29

ACTUAL

2009-02
2018-09-06
2018-09-06
Pharmacokinetics of Psilocybin in Normal Adult Volunteers

NCT02163707

Healthy
University of Wisconsin, Madison

PHASE1

Completed

Registry updated 2020-04-15

12

ACTUAL

2014-06
2015-12
2015-12
Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

NCT02145091

Healthy
Johns Hopkins University

PHASE1

Completed

Registry updated 2019-12-30

40

ACTUAL

2014-05
2019-12-26
2019-12-26
Measurement of Persisting Changes in Emotional Brain Functioning Produced by Psilocybin

NCT02971605

Healthy
Johns Hopkins University

PHASE1, PHASE2

Completed

Registry updated 2019-09-10

13

ACTUAL

2017-07-01
2018-08-21
2018-08-21
A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.

NCT03661125

Parkinson Disease Psychosis
King's College London

EARLY_PHASE1

Unknown status

Registry updated 2019-08-13

30

ESTIMATED

2019-04-11
2021-09-01
2021-09-01
Psychopharmacology of Psilocybin in Cancer Patients

NCT00465595

Depressive Symptoms · Anxiety · Cancer
Johns Hopkins University

PHASE2

Completed

Registry updated 2018-07-19

56

ACTUAL

2007-04
2014-12
2016-12
Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe Depression

NCT03380442

Severe Depression
University of Helsinki

PHASE2

Unknown status

Registry updated 2017-12-21

60

ESTIMATED

2018-09
2020-01
2021-09
Effects of Psilocybin and Spiritual Practice on Persisting Changes in Attitudes and Behavior

NCT00802282

Healthy
Johns Hopkins University

PHASE1

Completed

Registry updated 2016-02-24

75

ACTUAL

2009-08
2014-02
2014-05
Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

NCT01988311

Psilocybin · Hallucinogens · Pharmacologic Actions · Central Nervous System Agents · Therapeutic Uses · Psychotropic Drugs
Johns Hopkins University

PHASE1

Completed

Registry updated 2014-05-20

10

ESTIMATED

2013-05
2014-01
2014-05

Reported research facilities

Brown University School of Public HealthProvidence, Rhode Island, United States
National Institute of Aging, Clinical Research UnitBaltimore, Maryland, United States
St. Michael's Hospital, Unity Health TorontoToronto, Ontario, Canada
FLMiami, Florida, United States
FLOrlando, Florida, United States
ILChicago, Illinois, United States
MNEden Prairie, Minnesota, United States
NELincoln, Nebraska, United States
NVLas Vegas, Nevada, United States
NYNew York, New York, United States
BCNorth Vancouver, British Columbia, Canada
Centre for Addiction and Mental HealthToronto, Ontario, Canada
MD Anderson Cancer CenterHouston, Texas, United States
Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States
Emory University HospitalAtlanta, Georgia, United States
University of WisconsinMadison, Wisconsin, United States
Yale UniversityNew Haven, Connecticut, United States
Olin Neuropsychiatry Research CenterHartford, Connecticut, United States
Brigham and Women's HospitalBoston, Massachusetts, United States
Oregon Health & Science UniversityPortland, Oregon, United States
M Health Fairview DBT ProgramMinneapolis, Minnesota, United States
M Physicians St. Louis Park ClinicSaint Louis Park, Minnesota, United States
University of Alabama at BirminghamBirmingham, Alabama, United States
GHU Paris Psychiatrie and NeurosciencesParis, France
University of California San Francisco (UCSF) Department of NeurologySan Francisco, California, United States
University of Colorado Anschutz Medical CampusAurora, Colorado, United States
Emory University Brain Health CenterAtlanta, Georgia, United States
Dana-Farber Cancer InstituteBoston, Massachusetts, United States
University of Nebraska Medical CenterOmaha, Nebraska, United States
New York University Langone Health, Center for Psychedelic MedicineNew York, New York, United States
University Health NetworkToronto, Ontario, Canada
Center for Psychedelics and Consciousness Research in the Behavioral Biology Research CenterBaltimore, Maryland, United States
NYU Langone HealthNew York, New York, United States
Djavad Mowafaghian Centre for Brain HealthVancouver, British Columbia, Canada
Department of Psychiatry, University of Ottawa, The Ottawa HospitalOttawa, Ontario, Canada
Department of Psychiatry, University of Toronto, University Health Network,Toronto, Ontario, Canada
Center for Psychedelics and Consciousness ResearchBaltimore, Maryland, United States
University of CalgaryCalgary, Alberta, Canada
University of California San Francisco, Sandler Neuroscience BuildingSan Francisco, California, United States
The University of British Columbia - Okanagan CampusKelowna, British Columbia, Canada
Johns Hopkins University School of MedicineBaltimore, Maryland, United States
Outpatient CTRCAurora, Colorado, United States
University of Colorado Cancer CenterAurora, Colorado, United States
University of California, San FranciscoSan Francisco, California, United States
Arthur Child Comprehensive Cancer CentreCalgary, Alberta, Canada
Providence Care HospitalKingston, Ontario, Canada
UC San DiegoSan Diego, California, United States
MacAnxiety Research CentreHamilton, Ontario, Canada
ARQ National Psychotrauma Centre / ARQ Centrum'45Oegstgeest, Netherlands
Clinical Research Facility, King's College HospitalLondon, London, United Kingdom
Toronto Western Hospital (University Health Network)Toronto, Ontario, Canada
Connecticut Mental Health CenterNew Haven, Connecticut, United States
Vail Health Behavioral HealthEdwards, Colorado, United States
Psykiatrikliniken, Baravägen 1Lund, Sweden
5510 Nathan Shock DriveBaltimore, Maryland, United States
Birmingham VA Medical Center, Birmingham, ALBirmingham, Alabama, United States
Tuscaloosa VA Medical Center, Tuscaloosa, ALTuscaloosa, Alabama, United States
VA Portland Health Care System, Portland, ORPortland, Oregon, United States
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PAPhiladelphia, Pennsylvania, United States
VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, Washington, United States
UW School of Medicine and Public HealthMadison, Wisconsin, United States
The Parsons Research Center for Psychedelic HealingNew York, New York, United States
Athinoula A. Martinos Center for Biomedical ImagingCharlestown, Massachusetts, United States
University of Washington Center for Novel Therapeutics in Addiction PsychiatrySeattle, Washington, United States
The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United States
The University of Texas Health Science Center at HoustonHouston, Texas, United States
Roswell Park Cancer InstituteBuffalo, New York, United States
Kingston General Health Research InstituteKingston, Ontario, Canada
UCSF at Zuckerberg San Francisco General HospitalSan Francisco, California, United States
Lighthouse Psychiatry ScottsdaleGilbert, Arizona, United States
Clinical Innovations, Inc.Bellflower, California, United States
M3 Wake ResearchEncino, California, United States
The Regents of the University of California - San DiegoLa Jolla, California, United States
Kadima Neuropsychiatry InstituteLa Jolla, California, United States
CalNeuro Research Group, IncLos Angeles, California, United States
Catalina Research Institute, LLCMontclair, California, United States
Piedmont Hospital Neuroscience CentreOakland, California, United States
ATP Clinical Research, Inc.Orange, California, United States
CITrialsRiverside, California, United States
Lumos Clinical Research CenterSan Jose, California, United States
Syrentis Clinical ResearchSanta Ana, California, United States
Stanford UniversityStanford, California, United States
ASCLEPES Research CentersThousand Oaks, California, United States
Pacific Clinical Research Management Group, LLCUpland, California, United States
Innovative Clinical Research, Inc.Lauderhill, Florida, United States
Central Miami Medical Institute, LLCMiami, Florida, United States
Behavioral Clinical Research, Inc.Miami Lakes, Florida, United States
Health Synergy Clinical ResearchOkeechobee, Florida, United States
Clinical Neurosciecne Solutions, Inc. dba CNS HealthcareOrlando, Florida, United States
APG Research, LLC- Advanced Psychiatric GroupOrlando, Florida, United States
University South FloridaTampa, Florida, United States
Stedman Clinical TrialsTampa, Florida, United States
Health Synergy Clinical Research, LLCWest Palm Beach, Florida, United States
Atlanta Center for Medical ResearchAtlanta, Georgia, United States
iResearch AtlantaDecatur, Georgia, United States
Rush University Medical CenterChicago, Illinois, United States
Uptown Research Institute, LLCChicago, Illinois, United States
Psychiatric Medicine AssociatesSkokie, Illinois, United States
Harvard Medical School - McLean HospitalBelmont, Massachusetts, United States
Adams Clinical - Boston (Copley Clinical)Boston, Massachusetts, United States
University of Massachusetts Medical SchoolNorth Worcester, Massachusetts, United States
Adams Clinical - BostonWatertown, Massachusetts, United States
Michigan Clinical Research Institute PCAnn Arbor, Michigan, United States
University Of Michigan Comprehensive Depression CenterAnn Arbor, Michigan, United States
Institute for Integrative TherapiesEden Prairie, Minnesota, United States
St. Charles Psychiatric Associates - Midwest Research GroupSaint Charles, Missouri, United States
Alivation Research, LLC.Lincoln, Nebraska, United States
Hassman Research InstituteBerlin, New Jersey, United States
Princeton Medical InstitutePrinceton, New Jersey, United States
Bio Behavioral HealthToms River, New Jersey, United States
Dent Neurosciences Research Center, Inc.Amherst, New York, United States
Fieve Clinical Research, IncNew York, New York, United States
Spectrum Neuroscience and Treatment InstituteNew York, New York, United States
Adams Clinical - New YorkNew York, New York, United States
New York State Psychiatric InstituteNew York, New York, United States
Richmond Behavioral AssociatesStaten Island, New York, United States
Adams Clinical - New YorkThe Bronx, New York, United States
University of Cincinnati, Department of Psychiatry & Behavirol NeuroscienceCincinnati, Ohio, United States
Cleveland Clinic - Lutheran HospitalCleveland, Ohio, United States
The Ohio State UniversityColumbus, Ohio, United States
Suburban Research AssociatesMedia, Pennsylvania, United States
The University of Texas at Austin - Dell Medical SchoolAustin, Texas, United States
Houston Clinical Trials, LLCBellaire, Texas, United States
Relaro Medical TrialsDallas, Texas, United States
Center for Depression Research and Clinical CareDallas, Texas, United States
North Texas Clinical TrialsFort Worth, Texas, United States
Brain Health Consultants and TMS CenterHouston, Texas, United States
HCA Healthcare Research Institute - Medical City Green Oaks HospitalPlano, Texas, United States
Cedar Clinical ResearchDraper, Utah, United States
The University of Utah - Huntsman Mental Health InstituteSalt Lake City, Utah, United States
Seattle Neuropsychiatric Treatment CenterSeattle, Washington, United States
Diex Recherche Sherbrooke Inc.Québec, B.C., Canada
Medical Arts Health Research Centre, KamloopsKamloops, British Columbia, Canada
Okanagan Clinical TrialsKelowna, British Columbia, Canada
Medical Arts Research Group - PentictonPenticton, British Columbia, Canada
Chatham-Kent Clnical Trials CentreChatham, Ontario, Canada
St. Michael's HospitalToronto, Ontario, Canada
Centre for Addiction and Mental Health (CAMH)Toronto, Ontario, Canada
Centre for Neurology StudiesVancouver, Canada
Medical Arts Research GroupVancouver, Canada
National Institute of Mental HealthKlecany, Czechia
Neuroterapie KH SroKutná Hora, Czechia
Psychiatric AmbulanceOstrava, Czechia
A-Shine s.r.o.Pilsen, Czechia
Psychedelicka klinika, s.r.o.Prague, Czechia
Institut Neuropsychiatricke PecePrague, Czechia
Aalborg Universitetshospital-Psykiatrien Region NordjyllandAalborg, Denmark
Ghu-Centre Hospitalier Sainte Anne, Centre de Recherche CliniqueParis, Paris, France
Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire CaremeauNîmes, France
Universite Paris VI Pierre et Marie Curie - Hopital de La Salpetriere - Centre Emotion - USR 3246 (CNRS UMR 7593)Paris, France
Centre Hospitalier Sainte Anne - Clinique des Maladies Mentales et de l'Encephale (CMME)Paris, France
Charite-Universitaetsmedizin BerlinBerlin, Germany
Johann Wolfgang Goethe-Universitaet Frankfurt am Main - Klinik fuer Psychiatrie, Psychosomatik und PsychotherapieFrankfurt, Germany
ZiP Campus LuebeckLübeck, Germany
Tallaght University HospitalDublin, Ireland
La Nua Day Hospital Mental Health CentreGalway, Ireland
University Medical Center GroningenGroningen, Provincie Groningen, Netherlands
Leids Universitair Medisch Centrum (LUMC) (Leiden University Medical Center) - Leiden Institute for Brain and Cognition (LIBC)Leiden, Netherlands
Universitair Medisch Centrum Utrecht (UMC Utrecht)Utrecht, Netherlands
Promente - Ośrodek Badań KlinicznychBydgoszcz, Poland
Uniwersyteckle Centrum Kliniczne, Klinika Psychiatrii DoroslychGdansk, Poland
Centrum Badan Klinicznych PI-House Sp. z o.o.Gdansk, Poland
Hospital Clinic de BarcelonaBarcelona, Spain
Parc Sanitari Sant Joan de Deu (Sant Joan de Deu Serveis de Salut Mental)Barcelona, Spain
Hospital Universitario Fundacion Jimenez DiazMadrid, Spain
FIDMAG Hermanas HospitalariasSant Boi de Llobregat, Spain
Hospital Universitario Río Hortega de ValladolidValladolid, Spain
Hospital Provincial de Zamora - Servicio de PsiquiatriaZamora, Spain
VuxenpsykiatrimottagningenLandskrona, Sweden
Lunds Universitet - Medicinska Fakulteten (Lund University Faculty of Medicine)Lund, Sweden
ClinSmart Sweden ABSolna, Sweden
HälsoklustretStockholm, Sweden
Cornwall Partnership NHS Foundation TrustBodmin, Cornwall, United Kingdom
Abraham Cowley Unit - Surrey and Borders Partnership NHS Foundation TrustChertsey, United Kingdom
St. Pancras Clinical ResearchChester, United Kingdom
Grounded Research Hub - Rotherham Doncaster & South Humber NHS Foundation TrustDoncaster, United Kingdom
Clinical Research Facility, Royal Devon and Exeter HospitalExeter, United Kingdom
Fulbourn Hospital - Cambridgeshire And Peterborough NHS Foundation TrustFulbourn, United Kingdom
St. Pancras Clinical ResearchLondon, United Kingdom
King's College London - Institute of Psychiatry, PsychologyLondon, United Kingdom
Clerkenwell HealthLondon, United Kingdom
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust - Wolfson Research CentreNewcastle, United Kingdom
University Of Nottingham/Nottinghamshire Healthcare Trust, Institute Of Mental HealthNottingham, United Kingdom
The Warneford Hospital- NIHR Clinical Research FacilityOxford, United Kingdom
Sheffield Health and Social Care NHS Foundation TrustSheffield, United Kingdom
James J. Peters Department of Veterans Affairs Medical CenterThe Bronx, New York, United States
ProScience Research GroupCulver City, California, United States
Collaborative Neuroscience Network, LLCGarden Grove, California, United States
University California San DiegoLa Jolla, California, United States
California Center for Psychedelic TherapyLos Angeles, California, United States
Clarity Clinical Research, LLCLos Angeles, California, United States
Artemis Institute for Clinical ResearchSan Diego, California, United States
Comprehensive Psychiatric CareNorwich, Connecticut, United States
APG Research, LLCOrlando, Florida, United States
DMI Health Care Group, IncTampa, Florida, United States
Meridien Research/Accel ResearchTampa, Florida, United States
Psych AtlantaAtlanta, Georgia, United States
Emory UniversityAtlanta, Georgia, United States
Sheppard Pratt Health SystemBaltimore, Maryland, United States
CBH Health, LLCGaithersburg, Maryland, United States
Pharmasite Research, IncPikesville, Maryland, United States
University of MinnesotaMinneapolis, Minnesota, United States
University of MissouriColumbia, Missouri, United States
Midwest Research GroupSaint Charles, Missouri, United States
Washington University School of MedicineSt Louis, Missouri, United States
The Medical Research Network, LLCNew York, New York, United States
Insight Clinical Trials, LLCBeachwood, Ohio, United States
Neuro-Behaviroral Clinical Research, Inc.North Canton, Ohio, United States
Rivus Wellness & Research InstituteOklahoma City, Oklahoma, United States
Global Medical Institutes, LLC, Scranton Medical InstituteMoosic, Pennsylvania, United States
UT Health Science Center at Houston (UTHSC-H)Houston, Texas, United States
Core Clinical ResearchEverett, Washington, United States
Toronto Western Hospital - University Health NetworkToronto, Ontario, Canada
Johns Hopkins School of MedicineBaltimore, Maryland, United States
UPMC PresbyterianPittsburgh, Pennsylvania, United States
Univeristy of Southern California Brain and Creativity InstituteLos Angeles, California, United States
Department of Veterans AffairsWest Haven, Connecticut, United States
Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States
Toronto Western HospitalToronto, Ontario, Canada
Tel Aviv Sourasky Medical CenterTel Aviv, Israel
Scottsdale Research InstituteScottsdale, Arizona, United States
University of Wisconsin - MadisonMadison, Wisconsin, United States
Centro de Pesquisas Matteo RicciRio de Janeiro, Rio de Janeiro, Brazil
The Clinical and Translational Sciences Research CenterTucson, Arizona, United States
South London and Maudsley NHS Foundation TrustLondon, United Kingdom
University of Alabama Clinical Research UnitBirmingham, Alabama, United States
Preferred Research Partners-NWA, LLCFayetteville, Arkansas, United States
Preferred Research Partners, Inc.Little Rock, Arkansas, United States
West LA VA Medical Center - Mental Health DepartmentLos Angeles, California, United States
Pacific Neuroscience Institute (PNI) at Saint John's Physician PartnersSanta Monica, California, United States
Psychedelic Science InstituteSanta Monica, California, United States
Mountain View Clinical ResearchDenver, Colorado, United States
Connecticut Mental Health Center, Yale UniversityNew Haven, Connecticut, United States
Clinical Neuroscience Solutions Inc.Jacksonville, Florida, United States
Clinical Neuroscience Solutions, Inc.Orlando, Florida, United States
CenExel iResearch, LLCDecatur, Georgia, United States
Great Lakes Clinical TrialsChicago, Illinois, United States
Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States
Sunstone Medical PCRockville, Maryland, United States
VA Nebraska Western Iowa Health Care SystemOmaha, Nebraska, United States
Global Medical Institutes, LLC; Princeton Medical InstitutePrinceton, New Jersey, United States
University of New Mexico (UNM) Interdisciplinary Substance Use and Brain Injury (ISUBI) CenterAlbuquerque, New Mexico, United States
NYU Clinical & Translational Science InstituteNew York, New York, United States
Bronx Veterans Research Foundation at the James J. Peters VAMCThe Bronx, New York, United States
AIM Trials, LLCPlano, Texas, United States
Clinical Trials of Texas, LLCSan Antonio, Texas, United States
Cedar Clinical Research, Inc.Murray, Utah, United States
Seattle Neuropsychiatric Treatment CenterBellevue, Washington, United States
VA Portland Health Care SystemVancouver, Washington, United States
The Ohio State University Department of PsychiatryColumbus, Ohio, United States
BioPharma Services Inc.Toronto, Ontario, Canada
Institute of Health Science, Khyber Medical UniversityIslamabad, Capital, Pakistan
Hayatabad Medical Complex PeshawarPeshawar, KPK, Pakistan
Khyber Medical UniversityPeshawar, KPK, Pakistan
VA Connecticut Healthcare SystemWest Haven, Connecticut, United States
William Osler Health SystemBrampton, Ontario, Canada
St. Joseph's HealthcareLondon, Ontario, Canada
South Lake Regional Health CentreNewmarket, Ontario, Canada
Bruyere HealthOttawa, Ontario, Canada
The Ottawa HospitalOttawa, Ontario, Canada
McGill University Health CentreMontreal, Quebec, Canada
Bruyere Continuing CareOttawa, Ontario, Canada
University of California, BerkeleyBerkeley, California, United States
Connecticut Mental Health CenterHamden, Connecticut, United States
West Haven VA Medical CenterWest Haven, Connecticut, United States
University of PennsylvaniaPhiladelphia, Pennsylvania, United States
Centre Hospitalier de la Côte BasqueBayonne, France
CHU BesançonBesançon, France
CHU de BordeauxBordeaux, France
CHU BrestBrest, France
CH Le VinatierBron, France
CHU de NantesNantes, France
CHU de NîmesNîmes, France
CHU Saint-EtienneSaint-Priest, France
Sunstone Medical, PCRockville, Maryland, United States
New York UniversityNew York, New York, United States
University Hospital BaselBasel, Canton of Basel-City, Switzerland
The Ohio State University Medical CenterColumbus, Ohio, United States
Toronto General HospitalToronto, Ontario, Canada
University of VirginiaCharlottesville, Virginia, United States
Princess Margaret Cancer CentreToronto, Ontario, Canada
The University of Texas at Austin Dell Medical SchoolAustin, Texas, United States
Enact Research Collaborative (40 Temple St, 4th Floor)New Haven, Connecticut, United States
Yale Program for Psychedelic ResearchNew Haven, Connecticut, United States
UCSF Mission BaySan Francisco, California, United States
Interdisciplinary Substance Use and Brain Injury (ISUBI)Albuquerque, New Mexico, United States
UCLA Semel InstituteLos Angeles, California, United States
UAB Outpatient Clinical Research UnitBirmingham, Alabama, United States
Ohio State University Comprehensive Cancer CenterColumbus, Ohio, United States
University of Arizona-TucsonTucson, Arizona, United States
National Institute of Mental HealthPrague, Czechia
Bispebjerg HospitalCopenhagen, Denmark
Champalimaud FoundationLisbon, Portugal
UNC Chapel Hill Medical CenterChapel Hill, North Carolina, United States
Innovative Clinical Research, Inc. (formerly Segal Trials)Lauderhill, Florida, United States
University Hospital Basel, Division of Clinical Pharmacology and ToxicologyBasel, Switzerland
University Hospital Geneva, Palliative medicine departmentCollonge-Bellerive, Switzerland
Spital Uster AG, Division of Internal MedicineUster, Switzerland
University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative CareZurich, Switzerland
University of California San FranciscoSan Francisco, California, United States
Portland VA Health Care SystemVancouver, Washington, United States
Pacific Neuroscience InstituteSanta Monica, California, United States
Segal TrialsLauderhill, Florida, United States
Johns Hopkins UniversityBaltimore, Maryland, United States
New York University School of MedicineNew York, New York, United States
Jewish General HospitalMontreal, Quebec, Canada
region Västra GötalandGothenburg, Göteborg, Sweden
Norra Stockholms PsykiatriStockholm, Stockholm County, Sweden
Psykiatriska Kliniken, Akademiska SjukhusetUppsala, Uppsala County, Sweden
Örebro sjukhusÖrebro, Örebro County, Sweden
University of California, Los AngelesLos Angeles, California, United States
Clinical Pharmacology & Toxicology, University Hospital BaselBasel, Switzerland
Sunnybrook Health Sciences CentreToronto, Ontario, Canada
Goodman Hall, Dept of Psychiatry, Indiana UniversityIndianapolis, Indiana, United States
The Stark Neuroscience Building (Goodman Hall)Indianapolis, Indiana, United States
Federal University of Latin American IntegrationFoz do Iguaçu, Paraná, Brazil
Psychiatric Center Copenhagen, Frederiksberg HospitalFrederiksberg, Denmark
Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General PsychiatryVienna, State of Vienna, Austria
Queen's UniversityKingston, Ontario, Canada
UAB Beacon TowerBirmingham, Alabama, United States
Connecticut Mental Health Center - Yale School of MedicineNew Haven, Connecticut, United States
Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research CenterColumbus, Ohio, United States
Mind Medicine Australia ClinicAbbotsford, Victoria, Australia
Paratus Clinical Research MelbourneNorthcote, Victoria, Australia
Empax CentreLeederville, Western Australia, Australia
Care DimensionsDanvers, Massachusetts, United States
Hammersmith Medicines Research (HMR)London, United Kingdom
Johns HopkinsBaltimore, Maryland, United States
Hadassah Medical Organization, Jerusalem, IsraelJerusalem, Israel
Massachusetts General HospitalBoston, Massachusetts, United States
Nantes University HospitalNantes, France
Duke City Recovery ToolboxAlbuquerque, New Mexico, United States
University of New MexicoAlbuquerque, New Mexico, United States
StartCareBrooklyn, New York, United States
VIP Community Services, IncThe Bronx, New York, United States
Baylor College of MedicineHouston, Texas, United States
University of California, San DiegoSan Diego, California, United States
Psych ResearchToronto, Ontario, Canada
University of ChicagoChicago, Illinois, United States
Imperial College LondonLondon, United Kingdom
University of British Columbia - Okanagan CampusKelowna, British Columbia, Canada
University of Colorado Anschutz Medical campus (CU AMC)Aurora, Colorado, United States
University of Iowa Health CareIowa City, Iowa, United States
University College LondonLondon, United Kingdom
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600Austin, Texas, United States
Marin Cancer CareGreenbrae, California, United States
University of San FranciscoSan Francisco, California, United States
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterTorrance, California, United States
Sunstone TherapiesRockville, Maryland, United States
Psychiatrische Universitätsklinik ZürichZurich, Switzerland
Mental Health Center Beer ShevaBeersheba, Israel
Beer Sheva Mental Health CenterBeersheba, Israel
University of IowaIowa City, Iowa, United States
VA Connecticut Healthcare System, West Haven CampusWest Haven, Connecticut, United States
Washington UniversitySt Louis, Missouri, United States
LSU Health ShreveportShreveport, Louisiana, United States
Geneva University HospitalGeneva, Switzerland
Innertrek Patient Service CenterPortland, Oregon, United States
Maastricht UniversityMaastricht, Limburg, Netherlands
Leiden University Medical CenterLeiden, South Holland, Netherlands
King's College London Institute of Psychiatry, Psychology and NeuroscienceLondon, United Kingdom
Lady Reading Hospital, PakistanPeshawar, Khyber Pakhtunkhwa, Pakistan
CHU de Nîmes, Hôpital Universitaire CarémeauNîmes, France
Behavioral Pharmacology Research UnitBaltimore, Maryland, United States
Clinical Neuroscience Solutions IncJacksonville, Florida, United States
Elixia MA, LLCSpringfield, Massachusetts, United States
Aims TrialPlano, Texas, United States
King's College LondonLondon, United Kingdom
Emory University/Winship Cancer InstituteAtlanta, Georgia, United States
Brain Health Center at Executive ParkAtlanta, Georgia, United States
Icahn School of Medicine at Mount SinaiNew York, New York, United States
Kings College London, Institute of Psychiatry, Psychology and NeurologyLondon, United Kingdom
CMAX Clinical ResearchAdelaide, South Australia, Australia
National University of Natural MedicinePortland, Oregon, United States
Clinical Trial UnitBasel, Canton of Basel-City, Switzerland
Neuroimaging Research Branch, NIDA-IRPBaltimore, Maryland, United States
University of Wisconsin Hospital and ClinicsMadison, Wisconsin, United States
Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy ResearchNew York, New York, United States
Chronic Pain and Fatigue Research CenterAnn Arbor, Michigan, United States
University of OtagoChristchurch, New Zealand
St. Michael's Hospital. Unity Health TorontoToronto, Ontario, Canada
University HospitalBasel, Switzerland
Department of Nuclear Medicine, Bern University HospitalBern, Switzerland
Psychiatric University Hospital ZurichZurich, Switzerland
CHUNîmes, Nîmes, France
University of WashingtonSeattle, Washington, United States
Harbor-UCLA Medical CenterTorrance, California, United States
Charité Berlin, Campus Mitte, Department of Psychiatry and PsychotherapyBerlin, Germany
Central Institute of Mental Health (CIMH)Mannheim, Germany
Neurobiology Research Unit, RigshospitaletCopenhagen, Denmark
Altman Clinical and Translational Research InstituteSan Diego, California, United States
Dell Medical SchoolAustin, Texas, United States
University of FloridaGainesville, Florida, United States
Huntsman Mental Health InstituteSalt Lake City, Utah, United States
CIPPRes ClinicLondon, United Kingdom
Imperial College Hammersmith campusLondon, United Kingdom
CMAX Clinical Research Pty LtdAdelaide, South Australia, Australia
Ghent University HospitalGhent, Oost-Vlaanderen, Belgium
University of ArizonaTucson, Arizona, United States
Sabi MindCalgary, Alberta, Canada
Centre for Neurology StudiesSurrey, British Columbia, Canada
University of British Columbia, Department of Psychiatry, BRAIN LabVancouver, British Columbia, Canada
Centricity ResearchHalifax, Nova Scotia, Canada
Department of Psychiatry, Queen's UniversityKingston, Ontario, Canada
Research Center Oxidi Oy / Addiktum OyHelsinki, Finland
A-KlinikkaKouvola, Finland
Mentacare OyOulu, Finland
Addiktum OyTurku, Finland
VA Palo Alto Healthcare System/Stanford MedicinePalo Alto, California, United States
Brugmann University HospitalBrussels, Belgium
Psychiatric Center CopenhagenCopenhagen, Frederiksberg, Denmark
Behavioral Biology Research Center, Johns Hopkins BayviewBaltimore, Maryland, United States
KGK Science Inc.London, Ontario, Canada
Universtity Hospital BaselBasel, Switzerland
Northern Stockholm Spychiatry ClinicStockholm, Sweden
Huntsman Cancer InstituteSalt Lake City, Utah, United States
University Hospital Basel, Clinical Trial UnitBasel, Canton of Basel-City, Switzerland
Mount Sinai Comprehensive Cancer CenterMiami Beach, Florida, United States
Sheaf House, Tallaght HospitalDublin, Ireland
University of New Mexico Health Sciences CenterAlbuquerque, New Mexico, United States
Pharmaceutical Research UnitAmman, Jordan
Altasciences Clinical Kansas, IncOverland Park, Kansas, United States
Canadian Rapid Treatment Centre of Excellence (CRTCE)Mississauga, Ontario, Canada
Centre for Neurology Studies x UpstreamAbbotsford British Columbia, British Columbia, Canada
Halucenex Life Sciences Inc.Windsor, Nova Scotia, Canada
Combat StressLeatherhead, Surrey, United Kingdom
UWHealth, 600 Highland AvenueMadison, Wisconsin, United States
Altman Clinical and Translational Research Institute, University of CaliforniaSan Diego, California, United States
Stanford Department of PsychiatryStanford, California, United States
Mood and Anxiety Disorders Program Emory University School of MedicineAtlanta, Georgia, United States
Ray Worthy Psychiatry LLCNew Orleans, Louisiana, United States
UT Center of Excellence on Mood Disorders, University of Texas Health Science CenterHouston, Texas, United States
Canadian Rapid Treatment Centre of ExcellenceMississauga, Ontario, Canada
National Institute of Mental Health Czech RepublicKlecany, Czechia
Enhed for Psykiatrisk Forskning, Psykiatrien i AalborgAalborg, Denmark
Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Benjamin FranklinBerlin, Germany
Groningen University Medical CentreGroningen, Netherlands
Leiden University Medical CentreLeiden, Netherlands
Utrecht University Medical CentreUtrecht, Netherlands
Unidade de Neuropsiquiatria, Centro Clinico ChampalimaudLisbon, Portugal
Hospital de Dia NumanciaBarcelona, Spain
Institute Hospital del Mar of Medical Research (IMIM)Barcelona, Spain
Clinical Research and Imaging CentreBristol, Avon, United Kingdom
Wolfson Research Centre, Campus for Ageing and VitalityNewcastle upon Tyne, Tyne and Wear, United Kingdom
Greater Manchester Mental Health Foundation TrustManchester, United Kingdom
New York State Psychiatric Institute, 1051 Riverside DriveNew York, New York, United States
Pacific Treatment & Research in PsychedelicsSanta Monica, California, United States
Ross Allison NPI #1437519899 Administrator Of StudyBozeman, Montana, United States
Clinical and Translational Science Institute, NYU Langone Medical CenterNew York, New York, United States
Sheppard PrattBaltimore, Maryland, United States
Altman Clinical and Translational Research InstituteLa Jolla, California, United States
FMS Department of PsychiatryKingston, Jamaica
NYU Langone Medical Center/Tisch HospitalNew York, New York, United States
Private Practice P.GasserSolothurn, Canton of Solothurn, Switzerland
Instituto de Fisica de Buenos Aires (IFIBA)Buenos Aires, Argentina
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical CenterBaltimore, Maryland, United States
Maryland Oncology Hematology PARockville, Maryland, United States
NYU College of Dentistry Bluestone Center for Clinical ResearchNew York, New York, United States
University of Wisconsin, School of PharmacyMadison, Wisconsin, United States
Mitul MehtaLondon, Camberwell, United Kingdom
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview CampusBaltimore, Maryland, United States

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.